Lactobacillus plantarum induces genomic DNA-dependent and TLR9-mediated elafin secretion from Caco-2 cells

Yukihiro Hiramatsu,[1,2†] Daisuke Sakamoto,[1†] Tomomitsu Satho,[1*] Keiichi Irie,[1] Fumio Miake,[1] Minoru Maeda,[3] Nobuhiro Kashige[1]

Abstract

Background: Lactobacilli show anti-inflammatory effects in the human intestine, and their genomic DNA was identified as one of the anti-inflammatory components. Increased levels of the natural protease inhibitor elafin in the intestine plays an important role in protection against intestinal inflammation. However, there have been no previous reports regarding whether lactobacilli increase elafin levels.

Objective: This study was performed to investigate whether *Lactobacillus plantarum* induces elafin secretion from the human epithelial colorectal adenocarcinoma cell line, Caco-2. Moreover, we examined the roles of bacterial genomic DNA and toll-like receptor 9 (TLR9), a specific receptor of bacterial DNA, in this effect.

Methods: Elafin secretion from Caco-2 cells by live and heat-killed *L. plantarum* was measured. The analysis was also performed using DNase-treated *L. plantarum* and genomic DNA extracted from *L. plantarum*. We examined the role of TLR9 in elafin secretion by *L. plantarum* and its genomic DNA by suppressing TLR9 expression using RNAi in Caco-2 cells.

Results: Heat-killed *L. plantarum* time- and dose-dependently increased elafin secretion, whereas live *L. plantarum* had no such effect. The elafin secretion by heat-killed *L. plantarum* was partially abolished by DNase treatment of the bacterium. In addition, *L. plantarum* genomic DNA also increased elafin secretion. Furthermore, suppression of TLR9 expression partially or completely abolished elafin secretion by heat-killed *L. plantarum* and its genomic DNA.

Conclusion: Our results indicated that heat-killed *L. plantarum* induced genomic DNA-dependent and TLR9-mediated elafin secretion. The anti-inflammatory effects of lactobacilli may be mediated by increases in the levels of elafin in the intestine.

Key words: elafin, *Lactobacillus plantarum*, genomic DNA, toll-like receptor 9, anti-inflammatory effect

From:
[1] Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan
[2] Department of Molecular Bacteriology, Research Institute for Microbial Diseases, Osaka University, 3-1, Yamada-oka, Suita, Osaka 565-0871, Japan
[3] Kyusyu Medical Co. Ltd., Fukuoka Bio-Incubation Center (F-BIC), 1-1, Hyakunen-Koen, Kurume, Fukuoka 839-0864, Japan

* Corresponding author:
Tomomitsu Satho
Email: satho@fukuoka-u.ac.jp
[†] Y. Hiramatsu and D. Sakamoto contributed equally.

Introduction

Lactobacilli, which are normal components of the human gut microflora, have been used as both foods and medicines because of their beneficial effects on the health of the host. For example, treatment with lactobacilli has been reported to ameliorate human intestinal inflammation in patients with inflammatory bowel disease (IBD).[1] The genomic DNA, double-stranded RNA, and cell wall components of lactobacilli have been identified as components responsible for the anti-inflammatory effects.[2-5] Specifically, there have been a number of

reports regarding the anti-inflammatory effects of genomic DNA from lactobacilli.[5-9] Rachmilewitz et al. reported that intragastric administration of probiotic medical food VSL#3® (VSL Pharmaceuticals, Inc.), which consists of eight strains of lactic acid bacteria including lactobacilli, ameliorated the severity of colitis in a dextran sodium sulfate (DSS)-induced mouse model of IBD, whereas DNase-treated VSL#3® had no effect.[5] They also demonstrated that VSL#3® had no effect on the severity of DSS-induced colitis in mice deficient for

toll-like receptor 9 (TLR9), which is a specific receptor of bacterial DNA[10] and has been reported to play a role in one of the major pathways responsible for the anti-inflammatory effects of genomic DNA from lactobacilli.[6,8] Taken together, these observations suggest that the anti-inflammatory effects of lactobacilli are mediated by their genomic DNA, and TLR9 signaling is essential for these anti-inflammatory effects.

IBD, including Crohn's disease and ulcerative colitis, are chronic inflammatory disorders of the intestine. Although the etiology of IBD has yet to be determined, a number of mediators seem to play prominent roles in the pathogenesis of chronic inflammatory disorders. Recent studies have highlighted the roles of proteases and their endogenous inhibitors in the pathogenesis of enteritis.[11-14] Elevated proteolytic activities of several proteases have been detected in the intestinal tissues of IBD patients.[11] This increased proteolytic activity may result from decreased efficacy and expression of endogenous protease inhibitors.[12] These results suggest that the shift of protease/anti-protease balance toward a more proteolytic environment causes chronic inflammation in the intestine. Among the endogenous protease inhibitors, elafin is a natural inhibitor of the human neutrophil proteases, elastase and proteinase 3.[15,16] Elafin is mainly secreted from the epithelial cells of various tissues, including the intestine,[17] and exerts anti-inflammatory effects by protease inhibition and by restoring barrier function to damaged epithelial cells in the intestine.[13] The expression of elafin was downregulated in the intestinal tissues of IBD patients, and this was associated with increased elastase activity.[14] In addition, a previous study using transgenic mice expressing human elafin demonstrated that an increased level of human elafin in the intestine re-equilibrates the protease/anti-protease balance and prevents intestinal inflammation in DSS- and trinitrobenzene sulfonic acid (TNBS)-induced mouse models of IBD.[13] These observations suggest that an increased level of elafin in the intestine may be useful in the treatment of IBD.

In the present study, we hypothesized that lactobacilli may increase elafin secretion from intestinal epithelial cells, as both lactobacilli and increased levels of elafin are involved in intestinal anti-inflammatory effects. In this context, Motta et al. engineered recombinant human elafin-expressing lactic acid bacteria, including lactobacilli, and demonstrated that oral administration of these recombinant bacteria ameliorates the symptoms of inflammation in DSS-induced murine colitis.[14] However, the increase in elafin by lactobacilli in the intestine has not been characterized in rodent studies, because a rodent homolog of human elafin has not been identified. Therefore, we examined elafin secretion from the human epithelial colorectal adenocarcinoma cell line, Caco-2, a model of human intestinal epithelial cells, induced by *Lactobacillus plantarum*, which is widely used in the food industry due to its metabolic versatility, and it has been reported to show anti-inflammatory effects both *in vitro* and *in vivo*.[18,19] To elucidate the molecular basis underlying the upregulation of elafin secretion by *L. plantarum*, we examined the roles of the bacterial genomic DNA and TLR9 in this effect.

Methods

Bacterial strain and culture conditions

L. plantarum strain D2905 was used in this study.[20] The bacterium was grown at 27 °C, the optimal temperature for its culture, in MRS medium under static conditions. To produce heat-killed *L. plantarum*, an overnight culture was inoculated into MRS medium to an optical density at 600 nm (OD_{600}) of 0.05 and grown for 8 h. After centrifugation ($7,000 \times g$, 15 min, 4 °C) and two washes with PBS, the bacterium was incubated for 10 min at 65 °C. The bacterium was killed by this incubation (bacterial viability: 0.001%). This heat-killed bacterial preparation was used without centrifugation and washing in the following experiments. Furthermore, DNase-treated heat-killed *L. plantarum* was prepared by incubation with 5 μg/mL DNase I (Roche) for 16 h at 37 °C.

Preparation of genomic DNA from L. plantarum

Genomic DNA was extracted from an overnight culture of *L. plantarum* using a Gentra Puregene Yeast/Bact. Kit (Qiagen) according to the manufacturer's protocol. The concentration and purity of genomic DNA preparation were confirmed by measuring OD_{260}, and $OD_{260/280}$ and $OD_{260/230}$ ratios, respectively. Only genomic DNA with $OD_{260/280} > 1.8$ and $OD_{260/230} > 2.0$ was used for the experiments. Purified genomic DNA was tested for endotoxin contamination using Limulus Amebocyte Lysate QCL-1000 (Lonza).

Measurement of elafin secretion by L. plantarum

Caco-2 cells were used as described previously.[6] Aliquots of 2×10^5 Caco-2 cells were plated in each well of 24-well plates (Nunc). Cells were treated with three concentrations of live or heat-killed *L. plantarum* (1, 2, and 5×10^9 CFU/mL) for 12, 24, and 48 h. After incubation, cell supernatants were centrifuged at $15,000 \times g$ for 5 min at 4 °C. The concentration of elafin in the cell supernatants was determined using a human elafin ELISA kit (R & D Systems).

Measurement of elafin secretion by transfected L. plantarum genomic DNA

Aliquots of 2×10^5 Caco-2 cells were plated in each well of 24-well plates. Subsequently, 5 μL of *L. plantarum* genomic DNA (0.35, 0.7, and 1.7 mg/mL) was added to 245 μL of minimum essential medium (Invitrogen) containing 1% fetal bovine serum (Biowest). The genomic DNA solution was then added to 250 μL of medium containing 1.25 μL of siLentFect Lipid Reagent (Bio-Rad Laboratories) and incubated for 30 min at room temperature to produce the transfection mix. Caco-2 cells were transfected with the transfection mix for 12, 24, and 48 h. After incubation, elafin secretion was measured by ELISA as described above. As the genome size of *L. plantarum* is approximately 3 Mbp, 1, 2, and 5×10^9 CFU/mL of *L. plantarum* contain approximately 3.5, 7, and 17 μg/mL of genomic DNA, respectively. Therefore, we used these three concentrations of genomic DNA (3.5, 7, and 17 μg/mL) in this experiment.

Transfection of Caco-2 cells with TLR9-siRNA

TLR9 expression in Caco-2 cells was suppressed by RNAi, as described previously.[21] Briefly, aliquots of 2×10^5 Caco-2 cells plated in 24-well plates were transfected with 50 nM TLR9

-siRNA or scramble TLR9-siRNA (Bonac Corp.) as a negative control using siLentFect Lipid Reagent. After incubation for 24 h, the cells were treated with heat-killed *L. plantarum* (5 × 10⁹ CFU/ml) or transfected with *L. plantarum* genomic DNA (17 μg/mL) for 48 h as described above. The cell supernatants were collected, and the cellular protein extracts from Caco-2 cells were prepared with PRO-PREP Protein Extraction Solution (iNtRON Biotechnology) according to the manufacturer's protocol. The concentration of elafin in the cell supernatants was determined by ELISA. Suppression of TLR9 expression in the protein extracts of cells transfected with TLR9-siRNA, but not scramble TLR9-siRNA, was confirmed by Western blotting using an antibody to TLR9 as described previously.[6]

Detection of intracellular translocated genomic DNA

Aliquots of 2×10^5 Caco-2 cells were plated in each well of 24-well plates and treated with heat-killed *L. plantarum* (5 × 10⁹ CFU/ml) or *L. plantarum* genomic DNA (17 μg/mL) for various times (0, 0.5, 1, 3, 6, 24, and 48 h). After treatment, Caco-2 cells were trypsinized using trypsin-EDTA (Invitrogen) at 37 °C for 10 min. The cells were then collected and centrifuged at $1,000 \times g$ for 5 min and washed five times with PBS. DNA was extracted from Caco-2 cells using ISOGEN (Nippon Gene) according to the manufacturer's protocol. Detection of intracellular genomic DNA was performed by PCR based on the *L. plantarum*-specific 16S rRNA gene.[6] PCR was performed using KOD FX Neo (Toyobo) in 30-μL reaction mixtures containing 1 μg of DNA preparation and the following primers: sense 5'-TGGTATTGATTGGTGCTTGCA-3' and anti-sense 5'-CCACCTTCCTCCGGTTTGTCA-3'. PCR products were subjected to 1.5% agarose gel electrophoresis.

Statistical analysis

Data are presented as means ± standard deviations. Statistical analyses were performed using Origin Pro 8.1 (OriginLab). In all analyses, $P < 0.05$ was taken to indicate significance.

Results

Increase in elafin secretion by heat-killed L. plantarum

Treatment with heat-killed *L. plantarum* (5 × 10⁹ CFU/ml) significantly increased elafin secretion from Caco-2 cells, reaching 0.84 ng/mL after 48 h of treatment ($P < 0.01$ vs. medium alone by two-way ANOVA followed by Tukey's test) (**Figure 1A**). In contrast, elafin secretion remained close to the background level after 48 h of treatment with live *L. plantarum*. Therefore, heat-killed *L. plantarum* was used in the following experiments. As shown in **Figure 1B**, treatment for 48 h with heat-killed *L. plantarum* at 2 and 5 × 10⁹ CFU/mL significantly increased elafin secretion from Caco-2 cells compared to medium alone (0.38 and 0.84 ng/mL vs. 0.10 ng/mL, respectively; $P < 0.01$, one-way ANOVA followed by Tukey's test). In contrast, there was no significant difference in elafin secretion between cells treated with 1 × 10⁹ CFU/mL heat-killed *L. plantarum* and medium alone. These results indicated that heat-killed *L. plantarum* increased elafin secretion in a time- and dose-dependent manner.

Decrease in heat-killed L. plantarum-induced elafin secretion by DNase treatment

Treatment with DNase-treated and non-treated heat-killed *L. plantarum* significantly increased the level of elafin secretion from Caco-2 cells compared with medium alone (1.18 and 0.54 ng/mL vs. 0.20 ng/mL, respectively; $P < 0.01$, one-way ANOVA followed by Tukey's test). However, the level of elafin secretion in cells treated with DNase-treated heat-killed *L. plantarum* was significantly lower than that in cells treated with non-treated heat-killed *L. plantarum* ($P < 0.05$) (**Figure 2**). These observations indicated that DNase treatment partially abolished the increase in elafin secretion by heat-killed *L. plantarum*, although we could not exclude the possibility that DNase caused the decrease in elafin secretion by heat-killed *L. plantarum* regardless of the DNase activity.

Figure 1. Time- and dose-dependent increases in elafin secretion by heat-killed *Lactobacillus plantarum*.
Caco-2 cells were treated with live or heat-killed *L. plantarum* (5×10⁹ CFU/ml) for 12, 24, and 48 h (A), or with three concentrations of the heat-killed *L. plantarum* (1, 2, and 5×10⁹ CFU/ml) for 48 h (B). The elafin concentrations in the cell supernatants were determined by ELISA. Data are expressed as ng/ml and represent the means ± standard deviations of three separate experiments performed in triplicate. *$P < 0.05$, **$P < 0.01$ compared with medium alone.

Figure 2. Influence of DNase treatment on elafin secretion by heat-killed *Lactobacillus plantarum*.
Caco-2 cells were treated with DNase-treated (DNase (+)) or non-treated (DNase (–)) heat-killed *L. plantarum* (5×10^9 CFU/ml) for 48 h. The elafin concentrations in the cell supernatants were determined by ELISA. Data are expressed as ng/ml and represent the means ± standard deviations of three separate experiments performed in triplicate. **P < 0.01 compared with medium alone, #*P* < 0.05 compared with DNase non-treated heat-killed *L. plantarum*.

Increase in elafin secretion by L. plantarum genomic DNA

Transfection with *L. plantarum* genomic DNA (17 µg/mL) significantly increased elafin secretion from Caco-2 cells, reaching 0.33 ng/mL after 48 h of treatment (*P* < 0.01 vs. medium alone, two-way ANOVA followed by Tukey's test) (**Figure 3A**). As shown in **Figure 3B**, transfection with *L. plantarum* genomic DNA at 7 and 17 µg/mL for 48 h significantly increased elafin

secretion from Caco-2 cells compared with medium alone (0.17 and 0.33 ng/mL vs. 0.07 ng/ml, respectively; *P* < 0.01, one-way ANOVA followed by Tukey's test). In contrast, no significant change in elafin secretion was observed in those transfected with 3.5 µg/mL of genomic DNA compared to controls. These results indicated that *L. plantarum* genomic DNA increased elafin secretion in a time- and dose-dependent manner.

Mediation of TLR9 on elafin secretion by heat-killed L. plantarum and its genomic DNA

TLR9-siRNA-transfected Caco-2 cells showed decreased TLR9 expression compared to siRNA non-transfected and scramble TLR9-siRNA-transfected cells as a negative control (**Figure 4A**). This observation confirmed that TLR9-siRNA suppressed TLR9 expression in Caco-2 cells. Treatment with heat-killed *L. plantarum* significantly increased the level of elafin secretion in non-transfected cells, scramble TLR9-siRNA-transfected cells, and TLR9-siRNA-transfected cells (0.74, 0.80, and 0.39 ng/mL, respectively). On the other hand, treatment with *L. plantarum* genomic DNA significantly increased elafin secretion in non-transfected cells and scramble TLR9-siRNA-transfected cells (0.33 and 0.35 ng/mL, respectively), but the genomic DNA had no such effect in TLR9-siRNA-transfected cells (0.09 ng/mL). In addition, the levels of elafin secretion in TLR9-siRNA-transfected cells treated with heat-killed *L. plantarum* and *L. plantarum* genomic DNA were significantly lower than those in non-transfected cells and scramble TLR9-siRNA-transfected cells (*P* < 0.05 and *P* < 0.01, respectively; two-way ANOVA followed by Tukey's test) (**Figure 4B**). These observations indicated that suppression of TLR9 expression partially or completely abolished elafin secretion by heat-killed *L. plantarum* and its genomic DNA, respectively.

### Intracellular translocation of L. plantarum genomic DNA

Intracellular translocation of the genomic DNA was a prerequisite for recognition by TLR9, because TLR9 is localized in

Figure 3. Time- and dose-dependent elafin secretion by genomic DNA from *Lactobacillus plantarum*.
Caco-2 cells were transfected with *L. plantarum* genomic DNA (17 µg/ml) for 12, 24, or 48 h (A) or with three concentrations of the genomic DNA (3.5, 7, and 17 µg/ml) for 48 h (B). The elafin concentrations in the cell supernatants were determined by ELISA. Data are expressed as ng/ml and represent the means ± standard deviations of three separate experiments performed in triplicate. *P < 0.05, **P < 0.01 compared with medium alone.

Figure 4. Effects of TLR9 suppression on elafin secretion by heat-killed *Lactobacillus plantarum* and its genomic DNA.
TLR9-siRNA- and scramble TLR9-siRNA-transfected Caco-2 cells were treated with heat-killed *L. plantarum* (5×10^9 CFU/ml) or transfected with *L. plantarum* genomic DNA (17 µg/ml) for 48 h. (A) TLR9 expression in cellular protein extract was confirmed by Western blotting using anti-TLR9 antibody. β-actin was used as an internal control. Data are representative of three separate experiments. (B) The elafin concentrations in the cell supernatants were determined by ELISA. Data are expressed as ng/ml and represent the means ± standard deviations of three separate experiments performed in triplicate. $*P < 0.05$, $**P < 0.01$.

Figure 5. Intracellular translocation of genomic DNA from *Lactobacillus plantarum* in Caco-2 cells.
Caco-2 cells were treated with heat-killed *L. plantarum* (5×10^9 CFU/ml) or *L. plantarum* genomic DNA (17 µg/ml) for various times (0 – 48 h). Intracellular translocation of the genomic DNA was detected by PCR based on the coding sequence of the *L. plantarum*-specific 16S rRNA gene. Data are representative of three separate experiments. M; 100 bp DNA ladder marker.

the endosome and lysosome.[22] Therefore, we examined whether *L. plantarum* genomic DNA can be translocated into Caco-2 cells. *L. plantarum* genomic DNA was detected within Caco-2 cells at 3–24 h after treatment with heat-killed *L. plantarum*, and the genomic DNA was also detected within cells at 1–24 h after treatment (**Figure 5**). No *L. plantarum* genomic DNA was detected within cells following treatment with medium alone.

Discussion

The results of the present study indicated that treatment with heat-killed *L. plantarum* increased the level of elafin secretion from Caco-2 cells, which was partially dependent on the bacterial genomic DNA. Moreover, TLR9 was shown to be the primary mediator of elafin secretion by heat-killed *L. plantarum* and its genomic DNA. To our knowledge, this is the first report regarding induction of elafin secretion from intestinal epithelial cells by lactobacilli and the molecular mechanisms underlying this effect.

Over the past several decades, lactobacilli have been reported to show anti-inflammatory effects and have been used

to treat patients with IBD.[1] Increased elafin levels have been shown to play an important role in intestinal anti-inflammatory effects.[13,14] However, there have been no previous reports of increases in elafin levels induced by lactobacilli in the intestine. As elafin production has not been characterized in rodents, we examined whether lactobacilli could increase the level of elafin in the intestine using Caco-2 cells, and our results indicated that heat-killed *L. plantarum* increased elafin secretion from Caco-2 cells (**Figure 1**). These observations suggested that orally administered lactobacilli may increase elafin levels in the intestines of IBD patients. As the protease/anti-protease imbalance due to downregulation of elafin was shown to be involved in chronic inflammation in the intestine of IBD patients,[11-14] the increase in elafin levels by lactobacilli in the intestine may lead to re-equilibration of the protease/anti-protease balance and subsequently ameliorate inflammation in these patients. On the other hand, live *L. plantarum* had no effect on elafin secretion (**Figure 1**), although live lactobacilli therapy has been reported to ameliorate human IBD.[1] In general, orally administered live lactobacilli cannot survive in the low pH gastric environment, and the secretion of lysozymes, bile acid, and pancreatic fluid in the duodenum also influence the viability of the lactobacilli.[23,24] Consequently, the lactobacilli would be killed by these conditions prior to reaching the intestine. Thus, it is possible that orally administered live lactobacilli are killed, and then increase elafin secretion from human intestinal epithelial cells.

Genomic DNA has been identified as the principle anti-inflammatory component of lactobacilli.[5-9] Therefore, we hypothesized that the increase in elafin secretion by heat-killed *L. plantarum* depends on its genomic DNA. In the present study, DNase treatment partially abolished the increase in elafin secretion by heat-killed *L. plantarum* (**Figure 2**). Moreover, *L. plantarum* genomic DNA increased elafin secretion from Caco-2 cells, although to a lesser extent than heat-killed *L. plantarum* (**Figures 1 and 3**). These results indicated that the increase in elafin secretion by *L. plantarum* is partially mediated by its own genomic DNA and suggested that lactobacilli may exert anti-inflammatory effects through genomic DNA-dependent elafin secretion from epithelial cells in the human intestine. These observations also suggested that bacterial components other than genomic DNA may also be involved in the increase in elafin secretion by heat-killed *L. plantarum*. Previous studies showed that dsRNA and cell wall components are also anti-inflammatory components of lactobacilli.[2-4] Therefore, the increase in elafin secretion by heat-killed *L. plantarum* may be related not only genomic DNA but also to these other bacterial components.

The anti-inflammatory effects of lactobacilli genomic DNA are primarily mediated by TLR9 signaling.[5,6] Consistent with this, suppression of TLR9 completely abolished the increase in elafin secretion by *L. plantarum* genomic DNA in the present study (**Figure 4**). These observations indicated that TLR9 signaling is a major pathway responsible for the induction of elafin secretion by *L. plantarum* genomic DNA. However, suppression of TLR9 only partially abolished the increase in elafin secretion by heat-killed *L. plantarum*, suggesting that TLR9 is one, but not the only, mediator of elafin secretion by heat-killed *L. plantarum*. As bacterial components other than genomic DNA,

including dsRNA and cell wall components, may be involved in the upregulation of elafin secretion by heat-killed *L. plantarum*, the receptors for these bacterial components (i.e., TLR3 and TLR2)[25,26] may also partially regulate these effects. Further studies are required to fully elucidate the molecular mechanism of elafin secretion by heat-killed *L. plantarum*.

Overproduction of inflammatory cytokines results in the development of inflammation in the intestine. In fact, the levels of the inflammatory cytokine interleukin (IL)-8 have been shown to be increased in the intestine of IBD patients.[27] Therefore, it is important to examine IL-8 secretion in assessment of the level of inflammation in the intestine. Our previous study indicated that genomic DNA of lactobacilli decreased H_2O_2-induced IL-8 secretion from Caco-2 cells.[6] In addition, we identified an oligodeoxynucleotide (ODN), which markedly decreased H_2O_2-induced IL-8 secretion, from the genomic DNA of *L. casei*, and demonstrated that oral administration of this anti-inflammatory ODN to mice ameliorated DSS-induced murine colitis.[21] Therefore, suppression of IL-8 secretion *in vitro* is an important factor for ameliorating colitis in this *in vivo* model of IBD. In our preliminary study, we found that heat-killed *L. plantarum* and its genomic DNA decreased H_2O_2-induced IL-8 secretion from Caco-2 cells without inducing a pro-inflammatory response (data not shown). These observations suggested the possibility of an anti-inflammatory effect in an *in vivo* model of IBD by heat-killed *L. plantarum* and its genomic DNA. On the other hand, we also showed previously that suppression of TLR9 expression by RNAi abolished the decrease in H_2O_2-induced IL-8 secretion by lactobacilli genomic DNA and the anti-inflammatory ODN.[6,21] These observations indicated that the TLR9 signaling pathway plays a major role in mediating the decrease in IL-8 secretion. However, at present, we cannot explain the mechanism by which activation of the TLR9 signaling pathway results in the observed decrease in IL-8 secretion. The results of the present study indicated that *L. plantarum* genomic DNA increased elafin secretion from Caco-2 cells through TLR9 (**Figures 3 and 4**). Therefore, the increase in elafin levels may play important roles in the reduction of IL-8 secretion by lactobacilli genomic DNA, likely due to inhibition of pro-inflammatory proteases and restoration of barrier function to damaged epithelial cells.[13] Further studies of the increase in elafin levels may elucidate the mechanism by which the TLR9 signaling pathway induces the observed anti-inflammatory effects.

TLR9 is expressed in human epithelial cells, including Caco-2 cells, and is localized in the endosome and lysosome.[22] The bacterial genomic DNA must undergo translocation into Caco-2 cells to be recognized by TLR9. However, bacterial genomic DNA cannot translocate into mammalian cells because of its high molecular weight and hydrophilicity. Therefore, translocation of DNA into eukaryotic cells has generally been performed using transfection reagents, such as liposomes. In the present study, we confirmed that *L. plantarum* genomic DNA translocated into Caco-2 cells in the presence (**Figure 5**), but not in the absence (data not shown), of transfection reagent. However, translocation of genomic DNA was also observed in Caco-2 cells treated with heat-killed *L. plantarum*. At present, we cannot explain these observations. Previous

studies showed that *L. plantarum* produces a major polyamine, putrescine,[28] and that polyamines form a complex with and stabilize the DNA. This complex subsequently forms nanoparticles and is subsequently readily translocated into eukaryotic cells.[29,30] One possible explanation for the translocation of genomic DNA into Caco-2 cells treated with heat-killed *L. plantarum* is that the genomic DNA and polyamine contained in heat-killed *L. plantarum* may form such a complex, thus facilitating translocation of the genomic DNA into Caco-2 cells due to the transfection effect of the polyamine.

Conclusion

The results of the present study indicated that heat-killed *L. plantarum* increased the level of elafin secretion from Caco-2 cells, and the bacterial genomic DNA and TLR9 play crucial roles in this effect. Lactobacilli therapy is useful for the treatment of IBD, although the underlying mechanisms are not fully understood. Our observations suggest that one possible mechanism for the efficacy of lactobacilli therapy may involve an increase in elafin levels in the intestine. Further studies of the elafin induction associated with lactobacilli and their genomic DNA may lead to the development of novel therapeutic approaches to ameliorate intestinal inflammation.

Acknowledgement

References

1. Hart AL, Stagg AJ, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2003;36:111-9.
2. Noh SY, Kang S-S, Yun C-H, Han SH. Lipoteichoic acid from *Lactobacillus plantarum* inhibits Pam2CSK4-induced IL-8 production in human intestinal epithelial cells. Mol Immunol. 2015;64:183-9.
3. Kawashima T, Kosaka A, Yan H, Guo Z, Uchiyama R, Fukui R, et al. Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-β. Immunity. 2013;38:1187-97.
4. Matsumoto S, Hara T, Nagaoka M, Mike A, Mitsuyama K, Sako T, et al. A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. Immunology. 2009;128:e170-80.
5. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126:520-8.
6. Hiramatsu Y, Satho T, Irie K, Shiimura S, Okuno T, Sharmin T, et al. Differences in TLR9-dependent inhibitory effects of H2O2-induced IL-8 secretion and NF-kappa B/I kappa B-alpha system activation by genomic DNA from five Lactobacillus species. Microbes Infect. 2013;15:96-104.
7. Kim CH, Kim HG, Kim JY, Kim NR, Jung BJ, Jeong JH, et al. Probiotic genomic DNA reduces the production of pro-inflammatory cytokine tumor necrosis factor-alpha. FEMS Microbiol Lett. 2012;328:13-9.
8. Ghadimi D, Vrese M de, Heller KJ, Schrezenmeir J. Effect of natural commensal-origin DNA on toll-like receptor 9 (TLR9) signaling cascade, chemokine IL-8 expression, and barrier integrity of polarized intestinal epithelial cells. Inflamm Bowel Dis. 2010;16:410-27.
9. Luyer MD, Buurman WA, Hadfoune M, Speelmans G, Knol J, Jacobs JA, et al. Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock. Infect Immun. 2005;73:3686-92.
10. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-5.
11. Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007;117:636-47.
12. Schmid M, Fellermann K, Fritz P, Wiedow O, Stange EF, Wehkamp J. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol. 2007;81:907-15.
13. Motta J-P, Magne L, Descamps D, Rolland C, Squarzoni-Dale C, Rousset P, et al. Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology. 2011;140:1272-82.
14. Motta J-P, Bermúdez-Humarán LG, Deraison C, Martin L, Rolland C, Rousset P, et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med. 2012;4:158ra144.
15. Wiedow O, Lüademann J, Utecht B. Elafin is a potent inhibitor of proteinase 3. Biochem Biophys Res Commun. 1991;174:6-10.
16. Wiedow O, Schröder JM, Gregory H, Young JA, Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 1990;265:14791-5.
17. Suzuki Y, Furukawa M, Abe J, Kashiwagi M, Hirose S. Localization of porcine trappin-2 (SKALP/elafin) in trachea and large intestine by in situ hybridization and immunohistochemistry. Histochem Cell Biol. 2000;114:15-20.
18. Ko J-S, Yang H-R, Chang J-Y, Seo J-K. *Lactobacillus plantarum* inhibits epithelial barrier dysfunction and interleukin-8 secretion induced by tumor necrosis factor-α. World J Gastroenterol. 2007;13:1962-5.
19. Osman N, Adawi D, Ahrne S, Jeppsson B, Molin G. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig Dis Sci. 2004;49:320-7.
20. Maeda M, Shibata A, Biswas G, Korenaga H, Kono T, Itami T, et al. Isolation of lactic acid bacteria from kuruma shrimp (Marsupenaeus japonicus) intestine and assessment of immunomodulatory role of a selected strain as probiotic. 2014;16:181-92.
21. Hiramatsu Y, Satho T, Hyakutake M, Irie K, Mishima K, Miake F, et al. The anti-inflammatory effects of a high-frequency oligodeoxynucleotide from the genomic DNA of Lactobacillus casei. Int Immunopharmacol. 2014;23:139-47.
22. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004;5:190-8.
23. Goossens D, Jonkers D, Russel M, Thijs A, van den Bogaard A, Stobberingh E, et al. Survival of the probiotic, *L. plantarum* 299v and its effects on the faecal bacterial flora, with and without gastric acid inhibition. Dig Liver Dis. 2005;37:44-50.
24. Jacobsen CN, Rosenfeldt Nielsen V, Hayford AE, Møller PL, Michaelsen KF, Paerregaard A, et al. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by *in vitro* techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol. 1999;65:4949-56.
25. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature. 2001;413:732-8.
26. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem. 1999;274:17406-9.
27. Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene. 1999;18:6896-909.
28. Arena ME, Manca de Nadra MC. Biogenic amine production by Lactobacillus. J Appl Microbiol. 2001;90:158-62.
29. Vijayanathan V, Thomas T, Thomas TJ. DNA nanoparticles and development of DNA delivery vehicles for gene therapy. Biochemistry. 2002;41:14085-94.
30. Kleppe K, Osland A, Fosse V, Male R, Lossius I, Helland D, et al. Effect of polyamines on enzymes involved in DNA repair. Med Biol. 1981;59:374-80.

Common antibody dependent cell mediated cytotoxicity (ADCC) antibody epitopes of HIV-1 CRF01_AE Env and Gag in early HIV-1 infected individuals

Soraya Sangjan,[1,a] Silawun Ampol,[1,a] Sutchana Tabprasit,[2] Navin Horthongkham,[1] Thippawan Chuenchitra,[2] Pattama Ekpo,[3] Wannee Kantakamalakul,[1]*

Abstract

Background: There have been a few studies aimed at identifying epitopes of ADCC-inducing antibodies when compared to those of neutralizing antibodies and cytotoxic T lymphocytes against a variety of HIV-1 clades.

Objective: To map the common ADCC epitopes of HIV-1 CRF01_AE.

Methods: We screened 65 sera of confirmed early HIV-1 CRF01_AE infected individuals for ADCC antibody against gp120 utilizing an EGFP-CEM-NK^r flow cytometric assay. Sera with high ADCC antibody were then examined against ADCC epitopes using the complete HIV-1 CRF01_AE gp160- and subtype A Gag-overlapping peptide sets which were divided into 7 pools:E1-E7 and 5 pools:G1-G5, respectively. Each positive peptide pool was further investigated for fine ADCC epitope mapping using matrix formats.

Results: Twenty, 25 and 20 sera demonstrated the high-, medium- and low-ADCC antibody activities against gp120, respectively. Interestingly, 11 Env- and 6 Gag-peptides of pools E3, E4, E7 and pools G1, G2, G4 with high ADCC responses were also responded by at least 20%, 12% and 5%, 10% of medium- and low-ADCC antibody sera, respectively. These eleven common Env ADCC epitopes were localized at C2-V3-C3-V4 regions of gp120 and cytoplasmic tail of gp41 while six common Gag ADCC epitopes were localized at p17-p24-p2 regions.

Conclusions: Although the degree of ADCC antibody responses to the gp120 protein varied from high to low, there were certain consensus Env and Gag peptides that could induce the ADCC antibody responses of 21.54-58.46% and 23.08-41.54%, respectively of the early infected individuals. This epitope information should be useful as the new antibody-based vaccine immunogens.

Key words: ADCC antibody epitopes; HIV-1 CRF01_AE; Env; Gag; early infection

From:
1 Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
2 Research Division, Armed Forces Research Institute of Medical Sciences (AFRIMS)-Royal Thai Army, Bangkok, Thailand
3 Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

a Contributed equally to this article.

* **Corresponding author:**
   Wannee Kantakamalakul
   Email: wannee.kan@mahidol.ac.th

Introduction

The development of effective HIV-1 vaccines is urgently required for controlling future spread of HIV-1.[1] Current prophylaxis HIV-1 vaccine trials are based on both arms of immune responses, i.e., humoral and cellular immunity. However, each arm has not yet been successful.[2] Antibody dependent cell mediated cytotoxicity (ADCC) is a cytolytic mechanism of natural killer (NK) cells against virus-infected cells by combining of the innate and adaptive immunity. The mechanism of ADCC can be stimulated by the interaction of specific antibody bound to HIV-1 antigens on the infected cells and Fc receptor CD16 (FcγRIIIa) expressed on the surface of NK cells. Activation of NK cells lead to lysis of target cells.[3]

ADCC responses have been reported to correlate with the control or limit viremia during acute HIV-1 infection and help to slow the progression of disease in both HIV-1 infected individuals and SIV infected macaques.[4,5] Of the six HIV-1 efficacy trials, the RV144 prime-boost regimen phase III trial has provided evidence of vaccine-induced 31.2% protection.[2] Vaccinees who showed significantly low risk of HIV-1 infection demonstrated the high level of ADCC antibody responses.[6]

In the clinical course of HIV-1 infection, the acute phase of infection reveals an initial high peak of plasma viremia and decreased number of $CD4^+$ T lymphocytes.[7] In addition, expansion of inefficient HIV-1-specific $CD8^+$ T cells during acute infection has recently been reported.[8] Finding of the early effective immune responses against transmitted virus in acute HIV-1 infection may give a chance to control initial viremia, prolong HIV-1 disease progression, decrease immune cell damage and prevent transmission.[9] Identification of the common epitopes of HIV-1 that could respond to ADCC antibody of sera with low-, medium- or high-ADCC against envelope protein at the early phase would be an important new information that can be utilized for vaccine development. Here we have identified common ADCC antibody epitopes of Env and Gag of HIV-1 CRF01_AE using sera of confirmed early HIV-1 infected individuals.

Methods

Volunteer samples

All sera samples from young Thai men who were enrolled to the conscripts during year 2001-2013 were obtained with written informed consents following approval from Institutional Review Board (IRB) of Royal Thai Army Medical Department (Code: S034b/57) and IRB of the Faculty of Medicine Siriraj Hospital (COA: Si609/2014) prior to initiation of this study. The sera samples obtained had no individual identifiers. These sera were confirmed as early HIV-1 infection by using the Aware™ BED™ EIA HIV-1 Incidence Test (Calypte Co., Portland, OR, USA).

Cell line

The NK cell resistant, EGFP-CEM-NK[r] cells were cultured and prepared for the assay as previously described.[10]

Peptides

The gp120 of HIV-1 CRF01_AE CM243 (Protein Sciences, Meriden, CT, USA) was used to pulse the EGFP-CEM-NK[r] cells. In addition, the complete peptide set based on the HIV-1 CRF01_AE Env TH023/CM240 sequence consists of 168 peptides (122 peptides of TH023 gp120 and 46 peptides of TH023/CM240 gp41) each containing 15 amino acids (aa) in length, overlapping by 11 aa. The 143 peptides of TH023 were kindly provided by the Natural and Medical Sciences Institute (University of TÜbingen, Germany) and 25 peptides of CM240 were commercially synthesized (GenScript, Piscataway, NJ, USA). These Env peptides were divided into seven pools:E1-E7, each containing 24 peptides. To further identify the reactive peptide, each informative peptide pool was again divided into ten small pools according to the 5 by 5 matrix formats. Moreover, Gag peptide set of HIV-1 subtype A sequence consisting of 49 peptides each containing 20 aa in length, overlapping by 10 aa was kindly provided by the National Institutes of Health (NIH) AIDS reagent repository (catalog #3991). These Gag peptides were divided into five pools:G1-G5, each containing 9-10 peptides. Each pool was again divided into three small pools as 3 by 3 matrix formats. Each peptide pool was also used to pulse the EGFP-CEM-NK[r] cells.

Preparation of sera

All sera were from individuals infected with HIV-1 CRF01_AE as determined by C2-V4 nucleotide sequencing as described elsewhere.[11] A HIV-1 sero-negative pooled serum and a sero-positive serum with high ADCC antibody activity were used as controls with each assay. All sera were inactivated at 56 °C for 30 min. prior to use and used at dilutions of 1:250, 1:2,500 and 1:25,000.

Target cells

The gp120- or peptide pool-pulsed EGFP-CEM-NK[r] target cells were prepared by the addition of either 0.1 μg gp120 of HIV-1 CRF01_AE CM243 or 1 μg of each peptide pool to 1×10^5 target cells. The peptide and target cells were incubated for 1 h at room temperature. The gp120 pulsed cells were washed three times with phosphate buffered saline. The target cells were then re-suspended in growth medium containing RPMI 1640 (Gibco, Grand Island, NY) supplemented with 2 mM l-glutamine, 100 μg/ml streptomycin, 100 IU/ml penicillin, and 10% heat-inactivated fetal calf serum (Gibco) at a concentration of 1×10^5 cells/ml.

Effector cells

Cryopreserved peripheral blood mononuclear cells (PBMC) were prepared from leukopaks of a single HIV-1 seronegative blood donor as previously described.[10] Cells were later thawed and overlaid overnight at 1×10^6 cells/ml in growth medium at 37 °C with 5% CO2. The cells were then re-suspended in growth media at a concentration of 2.5×10^6 cells/ml and used as effector cells.

EGFP-ADCC flow cytometric assay

The EGFP-ADCC flow cytometric assay was based on a method previously described.[10] Lysis of target cells by ADCC activity was measured and analyzed with a FACScan flow cytometer (Becton Dickinson Biosciences {BDB}, San Jose, CA, USA). The actual percent lysis of target cells at each serum dilution was calculated as previously reported.[10] The cut-off for positive results using gp120- and peptide pool-pulsed target cells are 7.21% lysis and 5.46% lysis, respectively.[12]

Results

Screening for high ADCC antibody activity against gp120 pulsed target cells

Sixty five confirmed early HIV-1 CRF01_AE infected sera were investigated for ADCC antibody activity against gp120 pulsed target cells. The percent lysis of target cells ranged from 9.15 % to 56.12 % with mean and SD values of 24.08 and 10.72, respectively. Twenty, 25 and 20 sera demonstrated the high (> 29.44% target cell lysis, > mean + 0.5SD), medium

(29.44-18.72% lysis, mean ± 0.5SD) and low (< 18.72% lysis, < mean-0.5SD) ADCC antibody activities, respectively.

Identification of HIV-1 CRF01_AE gp160- and Gag-epitopes that are the target of ADCC reactive antibodies

Twenty sera with relatively high ADCC antibody activity were further examined against each of the seven peptide pools:E1-E7 of the HIV-1 CRF01_AE Env peptide set and each of the five peptide pools:G1-G5 of HIV-1 subtype A Gag formulated as described in the methods section. These 20 sera demonstrated positive ADCC antibody responses against a number of Env peptide pools while 18 sera responded against Gag peptide as shown in **Table 1**. For Env peptide pools, whereas sixteen (80%), fourteen (70%), and twelve (60%) sera demonstrated significantly higher frequency of ADCC responses against pools E7, E3 and E4, respectively, six to ten (30-50%) of these sera showed significant but somewhat lower frequency of ADCC responses to peptide pools E2, E1, E6 and E5. Moreover, 9/20 (45%) of tested sera demonstrated the responses to all three peptide pools: E3, E4, E7. In addition, all tested sera responded to at least one of these three peptide pools. Thus, a 5 by 5 matrix of each of the 3 peptide pools E3, E4 and E7 was selected to perform the fine epitope mapping of ADCC responses. The potential ADCC antibody epitopes were identified by verifying the common peptides from this

matrix. The common peptides within pools E3, E4 and E7 that responded to ADCC activity of each of the 20 tested sera are shown in **Table 2**. Twelve potential ADCC antibody epitopes with ≥ 50% responses of all tested sera in each pool were identified. For the parent E3 peptide pool, 9/14 (64.29%) and 7/14 (50%) sera showed ADCC activity against peptides (78, 83) and 71, respectively. For the parent E4 pool, 8/12 (66.67%), 7/12 (58.33%) and 6/12 (50%) of sera showed ADCC activity against peptides 87, (84, 85, 95, 97) and (89, 92), respectively. Moreover, 8/16 (50.00%) sera demonstrated ADCC activity against peptides 190 and 191 from the parent E7 pool.

For Gag peptide pools, whereas fourteen (70%), twelve (60%) and ten (50%) sera demonstrated significantly higher frequency of ADCC antibody responses against pools G4, G2 and G1, respectively, three to seven (15-35%) of these sera showed significant but somewhat lower frequency of ADCC responses to pools G3 and G5 (**Table 1**). In addition, 6/20 (30%) of tested sera recognized all three peptide pools: G1, G2, G4. However, two sera (10%) did not respond to any pool of Gag peptide. Thus, a 3 by 3 matrix of each of the 3 peptide pools G1, G2 and G4 was selected to perform the fine epitope mapping of ADCC responses. The common peptides within pools G1, G2 and G4 that responded to ADCC activity of each of the 18 sera tested are shown in **Table 3**. Six potential ADCC antibody epitopes with ≥ 50% responses of all tested sera in each pool

Table 1. Identification of peptide pools that are the targets of antibody dependent cell mediated cytotoxicity (ADCC) antibody responses in high ADCC antibody activity sera.

Serum No.	Obtained year	# Env peptide pools (E1-E7) response to ADCC antibody							# Gag peptide pools (G1-G5) response to ADCC antibody				
11	2001			3								-	
4	2007	1	2			5	6	7	1			4	
14	2007	1	2					7		2		4	5
10	2008	1					6	7				4	
15	2009	1		3	4	5		7		2	3	4	
3	2011			3			6					-	
11	2011	1	2	3		5		7	1	2		4	5
15	2011			3	4			7		2			5
16	2011			3	4			7	1	2			5
4	2012		2		4	5		7	1	2	3	4	5
5	2012			3	4	5	6	7		2			5
7	2012			3	4	5	6	7	1	2		4	
9	2012				4			7	1	2	3		
12	2012			3		5			1	2		4	
17	2012	1		3	4		6	7	1	2		4	
5	2013			3				7				4	
6	2013		2	3	4	5	6	7				4	
7	2013		2	3	4	5	6					4	5
8	2013	1		3	4	5		7	1	2		4	
9	2013			3	4		6	7	1			4	
Total		7	6	14	12	10	9	16	10	12	3	14	7

High ADCC antibody activity against HIV-1 gp120 pulsed target cells of twenty HIV-1 seropositive sera were analyzed for their individual responses to target cells pulsing with either each of 7 peptide pools (E1-E7) comprising the complete HIV-1 subtype CRF01_AE TH023/CM240 gp160 peptide set consisting of 168 peptides 15 amino acids in length or each of 5 peptide pools (G1-G5) comprising the complete HIV-1 subtype A Gag peptide set consisting of 49 peptides 20 amino acids in length. Each pool of Env- and Gag-peptides contains 24 and 9-10 peptides, respectively. Sera years of HIV-1 infection are also shown.

Table 2. Peptide mapping of high ADCC antibody sera against Env peptide pools E3, E4 and E7.

| Serum | | Single peptide number of Env pool responses to ADCC antibody | | | Total peptide responses |
No.	Obtained year	Env pool 3 (E3)	Env pool 4 (E4)	Env pool 7 (E7)	
11	2001	**78, 83**	-	-	2
4	2007	-	-	188, **190, 191**	3
14	2007	-	-	176, 181, 186	3
10	2008	-	-	175, 176, 180, 181, 185, 186, **190, 191**	8
15	2009	62, 65, 66, **83**	**87**, 88, **92**, 93, **97**, 98	177, 179, 186-189, **190, 191**	18
3	2011	**78**	-	-	1
11	2011	70, **71**, 75, 77, **78**, 82, **83**	-	181, **191**	9
15	2011	63, 65, 66, 68, 70, **71**, 75, 77, **78**, 80, 81, **83**	90, **92**, 94, **95, 97**, 99	179, 180	20
16	2011	70, **71**, 77, **78**, 82, **83**	**84, 85**, 86, **87**, 88, 90, 91, **92**, 93, **95**, 96, **97**, 98	178-180, 188, 189, **190**	25
4	2012	-	91, **92**, 96, **97**, 101, 102	177, 178, 181, 187, 188, **191**	12
5	2012	56, 57, 61, 62, 66, 67, **71**, 74, **78**, 79, **83**	86, **87**, 89	168, 173, 178, 180, 188, **190**	20
7	2012	62, 65, 66, 67, 70, **71**, 74, 77, **78**, 79, 82, **83**	**84, 85**, 86, **87**, 88	168-170, 173-175, 183-185	26
9	2012	-	**84, 85, 87**, 89	172-175, 187-189, **190**	12
12	2012	70, **71**	-	-	2
17	2012	56-59, 62-64, 67-69, **71**	**84, 85, 87, 89, 95, 97**, 99, 100, 102, 104	169, 171, 179, 181, 184, 186, 189, **190, 191**	29
5	2013	**78**	-	**191**	2
6	2013	56, 57, 67, 79	**87**, 90, **92, 95, 97**	167-169, 171, 182-184, 186	17
7	2013	-	**84, 85**, 86, **89, 95**, 96, 99, 105, 106, 109	-	10
8	2013	**71**, 74, 77, **78**, 79, 82, **83**	**84, 85**, 88, **89**, 90, 93, 94, **95**, 98-100, 103, 104	169, 170, 174, 175	24
9	2013	63, 66, 80, **83**	**84, 85, 87, 89**, 90, **92**, 94, **95, 97**, 99, 100, 102, 104	167, 169-172, 174-177, 179-182, 184-187, 189, **190, 191**	37

The peptide epitopes that showed ≥ 50% of ADCC antibody responses of all tested sera against each pool are shown in bold.

Table 3. Peptide mapping of high ADCC antibody sera against Gag peptide pools G1, G2, and G4.

| Serum | | Single peptide number of Gag pool responses to ADCC antibody | | | Total peptide responses |
No.	Obtained year	Gag pool 1 (G1)	Gag pool 2 (G2)	Gag pool 4 (G4)	
4	2007	3778	-	3797-8, 3803-4, 3806	6
14	2007	-	**3789, 3790**	3798-9, 3804-5	6
10	2008	-	-	3798-9, 3801, **3802**, 3804-5	6
15	2009	-	3784, **3789, 3790**, 3742	**3800**, 3801	6
11	2011	3775	3784, **3790**	**3800, 3802**	5
15	2011	-	3784, **3790**	-	2
16	2011	**3776, 3779**	**3789, 3790**, 3742	-	5
4	2012	3778, **3779**, 3780	3788, **3789, 3790**	**3800, 3802**, 3803	9
5	2012	-	3788, **3789**	-	2
7	2012	**3776, 3779**	3786, **3789**	**3800**, 3803	6
9	2012	**3776, 3779**	3784, **3789, 3790**, 3742	-	6
12	2012	**3776, 3779**	3784, 3786-7, **3789, 3790**, 3742	3797, **3800**, 3806	11
17	2012	3775, **3776**, 3777-8, **3779**, 3780	3782-7, 3742	3803	14
5	2013	-	-	**3800, 3802**	2
6	2013	-	-	3797, 3799, **3800, 3802**, 3806	5

The peptide epitopes that showed ≥ 50% of ADCC antibody responses of all tested sera against each pool are shown in bold.

Table 3. (Continued) Peptide mapping of high ADCC antibody sera against Gag peptide pools G1, G2, and G4.

Serum		Single peptide number of Gag pool responses to ADCC antibody			Total peptide responses
No.	Obtained year	Gag pool 1 (G1)	Gag pool 2 (G2)	Gag pool 4 (G4)	
7	2013	-	-	**3800**	1
8	2013	3772-5, **3776**, 3777, 3781	3782-8, **3789**, **3790**, 3742	**3802**	18
9	2013	3775, **3776**, 3777-8, **3779**, 3780	-	3801, **3802**	8

The peptide epitopes that showed ≥ 50% of ADCC antibody responses of all tested sera against each pool are shown in bold.

Table 4. Sequences of potential ADCC antibody epitopes of HIV-1 CRF01_AE Env TH023/CM240

Peptide Pool - No.	Potential ADCC Ab epitopes of HIV-1 CRF01_AE gp160	Amino acid #	Number of sera respond to ADCC epitopes of group			Total sera responses (%)	Glycoprotein location
			High responses (%)	Medium responses (%)	Low responses (%)		
3 - 71	TNNAK TIIVH LNKSV	280-294	8/20 (40)	7/25 (28)	3/20 (15)	18/65 (27.69)	gp120 (C2)
3 - 78	SINIG PGQVF YRTGD	308-322	9/20 (45)	18/25 (72)	11/20 (55)	38/65 (58.46)	gp120 (V3)
3 - 83	RKAYC EINGT KWNEV	328-342	9/20 (45)	6/25 (24)	2/20 (10)	17/65 (26.15)	gp120 (V3-C3)*
4 - 84	CEING TKWNE VLKKV	332-346	7/20 (35)	6/25 (24)	9/20 (45)	22/65 (33.85)	gp120 (C3)
4 - 85	GTKWN EVLKK VTKKL	336-350	7/20 (35)	11/25 (44)	10/20 (50)	28/65 (43.08)	gp120 (C3)
4 - 87	KKVTK KLKEH FNNKT	344-358	8/20 (40)	7/25 (28)	6/20 (30)	21/65 (32.31)	gp120 (C3)
4 - 89	EHFNN KTIIF QPPSG	352-366	6/20 (30)	7/25 (28)	11/20 (55)	23/65 (35.39)	gp120 (C3)
4 - 92	PSGGD LEITM HHFNC	364-378	6/20 (30)	11/25 (44)	15/20 (75)	32/65 (49.23)	gp120 (C3)
4 - 95	FNCRG EFFYC NTTRL	376-390	7/20 (35)	8/25 (32)	2/20 (10)	17/65 (26.15)	gp120 (C3-V4)**
4 - 97	YCNTT RLFNN TCMEN	384-398	7/20 (35)	0/25 (0)	0/20 (0)	7/65 (10.77)	gp120 (V4)
7 - 190	LSFQT PSHHQ REPDR	708-722	8/20 (40)	5/25 (20)	1/20 (5)	14/65 (21.54)	gp41 (CT)
7 - 191	TPSHH QREPD RPEGI	712-726	8/20 (40)	5/25 (20)	5/20 (25)	18/65 (27.69)	gp41 (CT)

C = constant region; V = variable region; CT = cytoplasmic tail
*V3 (aa 328-331) - C3 (aa 332-342); **C3 (aa 376-384) - V4 (aa 385-390)

Table 5. Sequences of potential ADCC antibody epitopes of HIV-1 CRF01_AE Gag

Peptide Pool - No.	Potential ADCC Ab epitopes of HIV-1 CRF01_AE Gag	Amino acid #	Number of sera respond to ADCC epitopes of group			Total sera responses (%)	Protein location
			High responses (%)	Medium responses (%)	Low responses (%)		
1 - 3776	LERFA LNPSL LETTE GCQQI	41-60	7/20 (35)	6/25 (24)	2/20 (10)	15/65 (23.08)	p17
1 - 3779	GTEEL RSLYN TVATL YCVHQ	71-90	7/20 (35)	8/25 (32)	7/20 (35)	22/65 (33.85)	p17
2 - 3789	MFSAL SEGAT PQDLN MMLNI	171-190	9/20 (45)	3/25 (12)	6/20 (30)	18/65 (27.69)	p24
2 - 3790	PQDLN MMLNI VGGHQ AAMQM	181-200	9/20 (45)	5/25 (20)	7/20 (35)	21/65 (32.31)	p24
4 - 3800	CKSIL RALGA GATLE EMMTA	330-350	6/20 (30)	8/25 (32)	9/20 (45)	23/65 (35.39)	p24
4 - 3802	CQGVG GPGHK ARVLA EAMSQV	350-370	6/20 (30)	13/25 (52)	8/20 (40)	27/65 (41.54)	p24-p2*

p17 = MA (matrix); p24 = CA (capsid)
*p24 (aa 350-363) - p2 (aa 364-370)

were identified. For the parent G1 peptide pool, 7/10 (70.00%) sera showed ADCC activity against peptides 3776 and 3779. For the parent G2 and G4 pools, 9/12 (75.00%) and 7/14 (50.00%) of the sera showed ADCC activity against peptides (3789, 3790) and (3800, 3802), respectively.

The responses of medium- and low-ADCC antibody sera against the common ADCC antibody epitopes of HIV-1 CRF01_AE Env and Gag that were identified in high ADCC antibody sera

Twenty five medium- and 20 low-ADCC antibody sera were examined for their responses to the 12 and 6 potential common

ADCC antibody epitopes of HIV-1 Env and Gag, respectively. For Env protein, the range of 5/25 (20%) - 18/25 (72%) and 1/20 (5%) - 15/20 (75%) of medium- and low-ADCC antibody sera, respectively demonstrated the responses to 11 common ADCC epitopes (peptides 71, 78, 83, 84, 85, 87, 89, 92, 95, 190, 191); i.e., except peptide 97 (**Table 4**). The overall responses of 65 tested sera against these peptides were > 20%, i.e., 21.54% - 58.46%. These 11 common epitopes located within the C2, V3, C3 and V4 of gp120 and the cytoplasmic tail (CT) of gp41 region.

For Gag protein, the range of 3/25 (12%) - 13/25 (52%) and 2/20 (10%) - 9/20 (45%) of medium- and low-ADCC antibody sera, respectively, demonstrated the responses to 6 common

ADCC epitopes (peptides 3776, 3779, 3789, 3790, 3800, 3802) (**Table 5**). The overall responses of 65 tested sera against these peptides were > 20%, i.e., 23.08% - 41.54%. These 6 common epitopes are localized within the p17, p24 and p2 regions of Gag protein.

Discussion

In this study, sixty five sera of young Thai men who enrolled to the conscripts were confirmed as sera from early HIV-1 CRF01_AE infected individuals using the Aware™ BED™ EIA HIV-1 Incidence Test (data not shown). Estimation of the mean duration of recent infection (MDRI) was 198.4 days for BED.[13] All sera were screened for high-, medium- and low-ADCC antibody activity against gp120 pulsed target cells utilizing an EGFP-CEM-NK^r flow cytometric assay. The gp120 was used instead of gp160 because only HIV-1 CRF01_AE gp120 is commercially available. Our assay measures the number of target cells that are killed.[10]

Identification of potential ADCC antibody epitopes using a matrix format led to the finding that the spectrum of peptide specific reactivity varied for each serum tested. All tested sera showed reactivity against a total of 1-37, and 1-18 peptides for Env and Gag proteins, respectively (**Tables 2, 3**). Studies on Env protein further showed that three epitopes (peptides 71, 78, 83) of pool E3, seven epitopes (peptides 84, 85, 87, 89, 92, 95, 97) of pool E4 and two epitopes (peptides 190, 191) of pool E7 were identified as being targets of ADCC antibodies from at least 50.00% of the tested sera (**Table 2**). Interestingly, all these potential epitopes except peptide 97 could be able to gain the responses from sera of medium- and low-ADCC activities for at least 20% and 5%, respectively which made the overall total responses to the range of 21.54-58.46% (**Table 4**). The aa sequences of the 12 potential ADCC epitopes of HIV-1 CRF01_AE gp160 are also shown in **Table 4**. The common peptides 71, 78, and 83 are localized within the C2, V3, and V3-C3 regions of gp120, respectively while the common peptides (84, 85, 87,

89, 92), 95 and 97 are localized within the C3, C3-V4 and V4 of gp120, respectively (**Figure 1**). In addition, the common peptides 190 and 191 are in the cytoplasmic tail region of gp41. Kijak et al. studied the molecular evolution of the HIV-1 epidemic among volunteers of RV144 vaccine trial from 2003 to 2009.[14] They found that CRF01_AE strains were 31% more diverse than the ones from the 1990s Thai epidemic. Thus, HIV-1 CRF01_AE strains that infected individuals in our study should also be diverse since the sera were obtained during 2001-2013. Interestingly, sera from these individuals could be able to demonstrate ADCC antibody responses to these common potent epitopes. This indicates that these ADCC epitopes were quite conserved and immunodominant.

Moreover, peptides 78, 85 and 92 showed the responses to ADCC activity at a larger number of sera of medium- and low-ADCC response groups than those of a high-ADCC response group, i.e., (72%, 55% vs 45%), (44%, 50% vs 35%), (44%, 75% vs 30%), respectively. This revealed the importance of these peptide sequences as the prominent ADCC epitopes for induction of ADCC responses against Env peptides of early HIV-1 infected individuals, i.e., 58.46%, 43.08% and 49.23%, respectively, of total 65 tested sera (**Table 4**).

Kulkarni et al. reported that 5 out of 10 Indian long-term non-progressors (LTNPs) demonstrated ADCC activity against the target epitopes in Env-C V3 region (aa 288-330: LNESVEI VCTRPNNNTRKSIRIGPGQTGDIIGDIRQAHC).[15] They proposed the potential role of this anti-V3 ADCC response in viral control which may contribute to the slower disease progressors. Their epitope sequences included our full epitope peptide 78 (aa 308-322: SINIGPGQVFYRTGD) and partial of epitope peptide 71 (aa 290-294:…LNKSV). The V3 region is one of the most immunogenic epitopes in the envelope which the V3 crown composed of the highly conserved aa I307, I309 and F317 that can induce specific antibody in > 90% of HIV infected individuals.[16,17] V3-specific Abs from RV144 vaccinees were shown to capture infectious virions.[18] Moreover,

Figure 1. Epitope distribution across the Env gp160 and Gag of HIV-1. ADCC antibody epitopes of HIV-1 CRF01_AE identified in this study are shown. The epitope sizes are not drawn to scale and the amino acid locations of the epitopes are aligned as close as possible with the true alignment. C = constant region; V = variable region; CT = cytoplasmic tail; KS = Kennedy sequence; MA = matrix; CA = capsid

Montefiori et al. demonstrated the high Nt antibody activity against V3 peptide of HIV-1 CRF01_AE TH023 (aa 302-326: SNNTRTSINIGPGQVFYRTGDIIGD) from volunteer sera of RV144 phase III trial.[19] The initial ADCC antibody response to the V3 epitopes in our study may occur against the founder virus in most of the early HIV-1 infected individuals. However, the later consequence may depend on the efficiency of each individual immune response. If one can control the virus as in LTNP, the ADCC antibody against these epitopes should be detectable for a longer time period. On the other hand, the virus may mutate the V3 sequence to evade the immune responses[20] and later ADCC antibody may be further adapted to recognize the coming mutated V3 epitopes. Thus, the ADCC antibody at the non-early phase would not be able to respond to these original V3 epitopes as we previously reported on ADCC epitopes of HIV-1 in asymptomatic infected individuals.[12] Our finding of peptide 85 (aa 336-350: GTKWNEVLKKVTKKL) as dominant ADCC epitope was also correspondent to the data of Kulkarni et al.[15] They demonstrated the recognition of novel antigenic ADCC epitope in sera of LTNPs at the C3 region (aa 331-360: CNISEEKWNKTLQRVSEKLKEHFPNKTIKF).

The CD4-bound conformation of Env was recently shown to be a major target of ADCC-mediating antibodies present in the sera of HIV-1-infected individuals.[21] Prévost et al. reported the influence of the envelope gp120 Phe 43 cavity on HIV-1 sensitivity to ADCC responses.[22] While residue S375 in the gp120 Phe 43 cavity is well conserved in the majority of group M HIV-1 isolates, CRF01_AE strains have a naturally occurring histidine at this position (H375). They demonstrated that the H375 increases Env propensity to sample the CD4-bound conformation, thus increasing susceptibility of HIV-1 infected cells to ADCC. They raise the intriguing possibility that the presence of His 375 in the circulating CRF01_AE strain in Thailand might have contributed to the efficacy of the trial by spontaneously exposing epitopes recognized by ADCC-mediating antibodies elicited by the RV144 vaccine regimen. Our finding on peptide 92 (aa 364-378: PSGGDLEITMHHFNC) with His 375 emphasized the immunodominant property of this peptide as ADCC epitope since 49.23% of tested sera showed the ADCC responses.

Tomaras et al. reported that the first anti-HIV-1 antibody was the antibody against gp41 and appeared 13 days after the appearance of plasma virus.[23] In our study, the common peptides 190 (aa 708-722: LSFQTPSHHQREPDR) and 191 (aa 712-726: TPSHHQREPDRPEGI) which are located in the Kennedy sequence (KS) of cytoplasmic tail (CT) region of gp41 showed the ability to induce ADCC antibody with the total responses of 21.54% and 27.69%, respectively, of 65 tested sera (**Table 4**). This confirmed the study of Dimmock et al. on the alternative topological model of CT sequence: external localization.[24] Moreover, anti-KE (Kennedy epitope) serum that could specifically neutralize HIV in vitro implied the localization of the KE on the outer surface of the virion.[25] Abacioglu et al. revealed that the KS epitope PDRPEG was a conformational epitope which could induce non-Nt antibody (Chessie 8) binding to HIV-infected cells.[26] This indicated the property of ADCC antibody inducible of our peptides as we demonstrated in our study.

Identification of ADCC antibodies targeting conserved non-Env proteins such as Gag may reveal more potent ADCC activities. The appearance of HIV-core antigens on the surface of infected cells has been shown for p17 and p24.[27,28] Moreover, the monoclonal antibodies (mAbs) to p24-core protein of HIV-1 have been demonstrated to mediate ADCC activity to destroy infected cells.[29] Our studies on Gag protein further demonstrated that two epitopes of each peptide pools G1 (peptides 3776, 3779), G2 (peptide 3789, 3790) and G4 (peptides 3800, 3802) were identified as being targets of ADCC antibodies from at least 50.00% of the sera tested (**Table 3**). Interestingly, all these 6 epitopes could be able to gain the responses from sera of medium- and low-ADCC activities for at least 12% and 10%, respectively which made the overall responses to the range of 23.08-41.54% (**Table 5**). The aa sequences of the 6 potential ADCC epitopes of HIV-1 CRF01_AE Gag are also shown in **Table 5**. The common peptides 3776 and 3779 are localized within the p17 (MA, matrix) region while the common peptides 3789, 3790 and 3800, 3802 are localized within the p24 (CA, capsid) region (**Figure 1**). Our finding of peptide 3789 (aa 171-190: MFSALSEGATPQDLNMMLNI) was correspondent to that of Grunow et al.[29] They showed the recognition of p24-ADCC epitope (aa 178-187: GATPQDLNIM) expressed on the HIV-infected T cells by mAbs. Interestingly, peptides 3779, 3800 and 3802 demonstrated the responses to ADCC activity at an almost equal/higher number of sera of medium- and low-ADCC response groups than those of a high-ADCC response group, i.e., (32%, 35% vs 35%), (32%, 45% vs 30%) and (52%, 40% vs 30%), respectively. This revealed the important of these peptide sequences as the dominant ADCC epitopes for induction of ADCC responses against Gag peptides of early HIV-1 infected individuals, i.e., 33.85%, 35.39% and 41.54%, respectively, of total 65 tested sera. Genetic data support a major role for the cytoplasmic tail of gp41 and the matrix domain of Gag in Env glycoprotein incorporation.[30] Both Gag and Env display properties of being associated with lipid rafts at the plasma membrane. Gag-Env interactions affect their co-recruitment to the virological synapse and subsequent early events in the next round of viral replication. The ADCC antibody against epitopes on matrix domain of Gag demonstrated in our study may have an effect on the new coming viral progeny at the Env incorporation process.

In conclusion, although the degree of ADCC antibody responses to the gp120 protein varied from high to low, there were certain potent consensus Env and Gag peptide epitopes that could induce the ADCC antibody responses in a majority of early infected individuals as shown in this study. This information should be useful for further design of the antibody epitope based vaccine. The pre-existing potent antibody induced by the vaccine should be able to limit the transmitted/founder viruses, delay acquisition, control viral replication and prevent the establishment of infection. Since cell-to-cell transmission appears to be more efficient than that of free virion for HIV-1 infection,[31] the ADCC responses would be a very important mechanism to eliminate the small number of virus-infected cells from an infected partner before the establishment of infection. Although, Nt antibodies have

no effect on cell-to-cell transmission of HIV-1,[32] their responses would be very crucial for eliminating free virions that may enter simultaneously with the viral infected cells during viral transmission. This warrants further study whether these ADCC epitopes also act as Nt antibody epitopes. Our studies are limited by the use of peptide/protein pulsed target cells instead of HIV-1 infected cells. The 3-dimentional structure of Env or Gag on the target cell surface may be not the same as those on the infected cells.

Acknowledgement

Author's contributions: SA, SS, ST and NH were contributors for performing experiments including collection of data, analysis; TC and PE oversaw the collection of data, analysis and interpretation; WK is the corresponding author and is the main contributor to the design and direction of the study including writing the manuscript.

References

1. McKinnon JE, Mellors JW, Swindells S. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther. 2009; 14:1-12.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-20.
3. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J. 1996;10:258-66.
4. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol. 2001; 75:6953-61.
5. Banks ND, Kinsey N, Clements J, Hildreth JE. Sustained antibody -dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses. 2002;18:1197-205.
6. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275-86.
7. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991;324:961-4.
8. Eller MA, Goonetilleke N, Tassaneetrithep B, Eller LA, Costanzo MC, Johnson S, et al. Expansion of inefficient HIV-specific CD8 T cells during acute infection. J Virol. 2016;90:4005-16.
9. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2010;10:11-23.
10. Kantakamalakul W, Pattanapanyasat K, Jongrakthaitae S, Assawadarachai V, Ampol S, Sutthent R. A novel EGFP-CEM-NKr flow cytometric method for measuring antibody dependent cell mediated-cytotoxicity (ADCC) activity in HIV 1 infected individuals. J Immunol Methods. 2006;315:1-10.
11. Sreepian A, Srisurapanon S, Horthongkham N, Tunsupasawasdikul S, Kaoriangudom S, Khusmith S, et al. Conserved neutralizing epitopes of HIV type 1 CRF01_AE against primary isolates in long-term nonprogressors. AIDS Res Hum Retroviruses. 2004;20:531-42.
12. Ampol S, Pattanapanyasat K, Sutthent R, Permpikul P, Kantakamalakul W. Comprehensive investigation of common antibody dependent cell mediated cytotoxicity (ADCC) antibody epitopes of HIV-1 CRF01_AE gp120. AIDS Res Hum Retroviruses. 2012;28:1250-8.
13. Hanson DL, Song R, Masciotra S, Hernandez A, Dobbs TL, Parekh BS, et al. Mean recency period for estimation of HIV-1 incidence with the BED -Capture EIA and Bio-Rad avidity in persons diagnosed in the United States with subtype B. PLoS ONE. 2016;11(4): e0152327.
14. Kijak GH, Tovanabutra S, Rerks-Ngarm S, Nitayaphan S, Eamsila C, Kunasol P, et al. Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial. J Virol. 2013; 87:7265-81.
15. Kulkarni A, Kurle S, Shete A, Ghate M, Godbole S, Madhavi V, et al. Indian long-term non-progressors show broad ADCC responses with preferential recognition of V3 region of envelope and a region from Tat protein. Front Immunol. 2017;8:5.
16. Zolla-Pazner S, Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol. 2010;10:527-35.
17. Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny MK, et al. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol. 2010;17:955-61.
18. Liu P, Yates NL, Shen X, Bonsignori M, Moody MA, Liao HX, et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol. 2013;87:7828-36.
19. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012;206: 431-41.
20. Zolla-Pazner S, Edlefsen PT, Rolland M, Kong XP, deCamp A, Gottardo R, et al. Vaccine induced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses. E Bio Medicine. 2014;1:37-45.
21. Veillette M, Coutu M, Richard J, Batraville LA, Dagher O, Bernard N, et al. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol. 2015; 89:545-51.
22. Prévost J, Zoubchenok D, Richard J, Veillette M, Pacheco B, Coutu M, et al. Influence of the envelope gp120 Phe 43 cavity on HIV-1 sensitivity to antibody-dependent cell-mediated cytotoxicity responses. J Virol. 2017;91(7).
23. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008;82:12449-63.
24. Dimmock NJ. The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis. Rev Med Virol. 2005;15:365-81.
25. Chanh TC, Dreesman GR, Kanda P, Linette GP, Sparrow JT, Ho DD. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 1986;5:3065-71.
26. Abacioglu YH, Fouts TR, Laman JD, Claassen E, Pincus SH, Moore JP, et al. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses. 1994;10:371-81.
27. Shang F, Huang H, Revesz K, Chen HC, Herz R, Pinter A. Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells. J Virol. 1991;65:4798-804.
28. Laurent AG, Krust B, Rey MA, Montagnier L, Hovanessian AG. Cell surface expression of several species of human immunodeficiency virus type 1 major core protein. J Virol. 1989;63:4074-8.
29. Grunow R, Franke L, Hinkula J, Wahren B, Fenyö EM, Jondal M, et al. Monoclonal antibodies to p24-core protein of HIV-1 mediate ADCC and inhibit virus spread in vitro. Clin Diagn Virol. 1995;3:221-31.
30. Checkley MA, Luttge BG, Freed EO. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol. 2011;410:582-608.
31. Evans LA, McHugh TM, Stites DP, Levy JA. Differential ability of human immunodeficiency virus isolates to productively infect human cells. J Immunol. 1987;138:3415-8.
32. Gupta P, Balachandran R, Ho M, Enrico A, Rinaido C. Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody. J Virol. 1989;63:2361-5.

Lymphocyte subsets and natural killer cell cytotoxicity in intravenous drug users with HIV-1 infection among Thai population

Wannee Kantakamalakul,[1] Suwalee Jangkhum,[1] Silawun Ampol,[1] Porurtai Burupharat,[2] Rutt Chuachoowong,[1,a]
Ruengpung Sutthent,[1] Kovit Pattanapanyasat,[3]*

Abstract

Background: Intravenous drug users (IVDUs) are among the high-risk groups who are most vulnerable to HIV infection. Several illicit drugs alter host immune function with increased incidence of infections including that of HIV. Many studies of the immune response of NK cells in HIV-1 seronegative IVDUs and HIV-1 seropositive IVDUs have been published from the Western countries and yet no data is available from Thailand.

Objective: To determine natural killer cell cytotoxicity and lymphocyte subsets in Thai HIV-1 infected intravenous drug users.

Methods: The NK cell cytotoxic function was determined using our well-established EGFP-K562 flow cytometric assay in 30 IVDUs with HIV-1 infection (IVH) comparing with those from the same number of non-infected IVDUs (IVX), HIV-1 seropositive individuals (HIV-1+ve) and healthy controls. The percentage and the absolute number of NK cells, helper CD4+ T cells and cytotoxic CD8+ T cells were also investigated.

Results: Among the study groups, IVH showed not only the lowest percentage of lytic activity by NK cells, but also a decline in the percentage and absolute count of NK cells. A decline in helper CD4+ T cells and an increase of cytotoxic CD8+ T cells of IVH group when compared to those of other 3 groups were also demonstrated.

Conclusions: The failure of innate immune NK cell function and their number in IVH may support the involvement of additional components of the immune system in the control of HIV-1 disease.

Key words: NK cells; NK cell cytotoxicity; CD4+ T cells; CD8+ T cells; HIV-1; intravenous drug users

From:
[1] Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
[2] The Public Health Center 3 (Bang Sue), Health Department, Bangkok Metropolitan Administration, Bangkok, Thailand
[3] Center of Excellence for Flow Cytometry, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

[a] **Present address:**
Sanofi-Aventis (Thailand) Ltd., Thailand

* **Corresponding author:**
Kovit Pattanapanyasat
Email: kovit.pat@mahidol.ac.th

Introduction

Human immunodeficiency virus (HIV)/AIDS is still a major global health problem with an estimated 35.3 million people are living with HIV.[1] In Thailand, more than 1 million of HIV-1 infected people were reported in 2015.[2] Of the estimated 440,000 people living with HIV, the relatively high levels of prevalence were in men who have sex with men, transgender people, male/female sex workers and their partners, migrant workers and intravenous drug users (IVDUs).

Interestingly, the HIV-1 prevalence among the Thai IVDUs has the highest HIV-1 prevalence (about 30-50%) comparing to other risk groups of HIV-1 infection[3] with predominantly a CRF01_AE subtype.[4-6] It has been known that illicit drugs alter immune unction and decrease host resistance to microbes with increased incidence of infections or immune disorders in humans, including infection with HIV and disease progression to AIDS.[7,8]

Human natural killer (NK) cells are large granular lympho-cytes of the innate immune system.[9] NK cells are recognized as a subset of cytotoxic innate lymphoid cells which play a role in the killing of tumor and virus-infected cells and participate in shaping the adaptive immunity by secretion of cytokines.[10] NK cells are cytotoxic with small granules in their cytoplasm contain proteins such as perforin and proteases known as granzymes, these proteins are released when they encounter with an infected cell by inducing either apoptosis or osmotic cell lysis.[11,12] NK cells can also recognize and lyse target cells by antibody dependent cell-mediated cytotoxicity (ADCC). The increased risk for the disease progression in HIV-infected individuals are associated not only with the low number of the NK cells but also with the defect in their cytotoxic activity[11] and also with decline of helper CD4[+] T cells and the accumulation of cytotoxic CD8[+] T cells.[13,14]

Although there are many studies of the innate immune response of NK cells in HIV-1 seronegative IVDUs and HIV-1 seropositive IVDUs,[15-18] the study of NK cells due to the HIV-1 infection and/or intravenous drug abuse in Thais has not been conducted. In this study, we used our well-established enhanced green fluorescent protein (EGFP)-K562 flow cyto-metric method[19] for measuring the NK cell function in IVDUs with HIV-1 infection (IVH). Results were also compared with those from HIV-1 infected individuals (HIV-1+ve) and non-infected IVDUs (IVX) as well as healthy individuals.

Methods
Study population and blood samples
Thirty HIV-1 uninfected IVDUs, 22 males and 8 females, and 30 HIV-1 infected IVDUs, 24 males and 6 females, at Public Health Center 3 (Bang Sue), Health Department, Bangkok Metropolitan Administration were enrolled in this study with written informed consents. All volunteers were documented to have treatment for drug addiction. All 30 HIV-1 infected IVDUs had previously tested once for HIV-1 antigen in saliva at this center. Fresh venipuncture Acid citrate dextrose solution B (ACD, Becton Dickinson Biosciences {BDB}, CA, USA) blood samples and Tripotassiumethylenedi-amine tetra-acetate (K_3EDTA, BDB) blood samples from each subject were collected. Complete blood counts (CBC) of each blood sample was performed at the laboratory of Department of Clinical Pathology, Faculty of Medicine Siriraj Hospital by using automate hematological analyzer Sysmex XE-5000 (Sysmex Corporation, Kobe, Japan).

Leuko-pak and K_3EDTA blood from 30 asymptomatic HIV-1 infected blood donors, 22 males and 8 females, were kindly provided by the Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital and Thai Red Cross. Thirty healthy HIV-1 seronegative blood subjects, 23 males and 7 females were also recruited from the blood bank donors. All samples obtained had no donor identifiers. There were no differences in the base line characteristics of all 4 study groups, i.e., age, sex ratio.

This study was approved by Ethics Committee of the Bang-kok Metropolitan Administration for IVDUs subjects (No. 147-2009) and Institutional Review Board, Faculty of Medicine Siriraj Hospital (COA: Si031/2007) for all samples.

Immunophenotyping staining of peripheral blood samples
Percentages and absolute cell numbers of NK cells (CD3[-]CD16[+]CD56[+]), helper CD4[+]T cells (CD3[+]CD4[+]) and cytotoxic CD8[+]T cells (CD3[+]CD8[+]) were determined by standard TriT-ESTmethod[20,21] using BD Tritest™ monoclonal antibody (mAb) reagents. Briefly, ten μl of TriTEST 3-color mAb reagents were mixed with 50 μl of EDTA-anticoagulated whole blood and incubated for 20 min at room temperature in the dark before adding 450 μl of FACS Lysing Solution (BDB). After an incubation time of 15 min, the cells were washed at 1,400 rpm for 5 min. The cell pellet was resuspended in 300 μl of 1% paraformaldehyde and kept at 2-8°C until analysis by FACSCalibur flow cytometer (BDB). Percentages of NK cells, helper CD4[+] T cells and cytotoxic CD8[+] T cells were obtained by using CellQuest™ Analysis software (BDB). The absolute cell numbers of these lymphocyte subsets were determined by multiplying the percentage of each subset with the absolute lymphocyte counts from the CBC.

Preparation of effector cells
Peripheral blood mononuclear cells (PBMCs) from each ACD blood sample were separated by standard ficoll-hypaque density gradient centrifugation, washed three times with 0.2 M phosphate buffered saline (PBS) and resuspended in freezing medium containing 60% RPMI 1640 (Gibco Laboratories, Grand Island, NY, USA), 30% fetal bovine serum (FBS, Gibco Laboratories) and 10% dimethyl sulfoxide (Sigma-Aldrich Corp, MO, USA). Aliquots of PBMCs at a density of 5×10^6 cells/ml were cryopreserved in liquid nitrogen until use. One day prior to the experiment, PBMCs were thawed and added to 100 mm polystyrene tissue culture plates (Griener Bio-One GmbH, Frickenhausen, Germany) and incubated overnight at 37°C with 5% CO_2 to deplete adherent monocytes. The non-adherent lymphocytes were collected and resuspended at a density of 1×10^6 for use as effector cells in the NK cell cytotox-icity assay.

Preparation of target cells
The EGFP-K562 cell line was prepared as previously de-scribed[19] and used as targets for measuring NK cell cytotoxicity by flow cytometry. This cell line was cultured in growth medium containing RPMI 1640 supplemented with 2 mM L-glutamine (Gibco Laboratories), 100 μg/ml streptomycin (Gibco Laboratories), 100 IU/ml penicillin (Gibco Laborato-ries), and 10% heat inactivated FBS (Gibco Laboratories) and 400 μg/ml of neomycin analogue G-418 (Roche Diagnostics, IN, USA). Prior to the experiment, the target cells were resuspended in growth medium at a density of 1×10^5 cells/ml.

NK cytotoxicity flow cytometry assay
The EGFP-K562 flow cytometric assay for measuring NK cytotoxicity was based on a method previously described.[19] Briefly, four hundred microliters of PBMCs as effector cells at a density of 1×10^6 cells/ml were added into individual round bottom 12×75 mm polystyrene (Falcon) tubes (BDB) with 2-fold serial diluted in 10% RPMI 1640 growth medium. Fifty microliters of EGFP-K562 target cells as a density of 1×10^5 cells/ml were added into each tube to yield the effectors per

target cells (E/T) ratios of 80:1 and 40:1. All sample tubes were mixed and incubated at 37°C with 5% CO_2 for 4 hours. After incubation, propidium iodide (PI) (Sigma-Aldrich Corp) solution at a concentration of 100 µg/ml was added into the tubes to stain compromised or dead cells and then the tubes were incubated at room temperature for 10 minutes. The cytotoxic activity of NK cells to lyse target cells was measured by using a FACSCalibur flow cytometer (BDB). For measuring the percent lysis of NK cytotoxicity, exactly 2×10^4 events per test sample were examined and no gating was used for acquisition. The threshold for side scatter (SSC) was set on the linear scale to discriminate the debris and dead cells. Two parameters of the forward and side scatter (FSC/SSC) dot plots signals were analyzed by using CELLQuest™ software (BDB) (**Figure 1A**). The EGFP versus PI data were obtained to evaluate live and dead target cells using log scale of green fluorescent (FL1) or EGFP in the X axis and the log scale of red fluorescent (FL2) or PI in the Y axis (**Figure 1B**). The strong green fluorescent at the lower right (LR) quadrant were identified as the live target cells whereas the red and green fluorescent on the upper right (UR) quadrant were identified as compromised or dead target cells. The red fluorescence on the upper left (UL) quadrant were defined as the autodamaged or potentially lysed effector cells or target cells with decreased EGFP whereas the lower left (LL) were considered to be the living effecter cells or living

target cells with weak green fluorescence. Effector cells alone and target cells alone stained with PI were used as controls. The percentage of target cell lysis was calculated by using the following formula: % Lysis = (UR/UR + LR) × 100.

Statistical analysis

Statistical analysis in this study was conducted on SPSS software version 11.5 (SPSS Inc., NY, USA). Statistical significance within group was analyzed by Shapiro-Wilk test and statistical significance between groups was analyzed with one-way ANOVA test. The significant level of each test between groups was adjusted by multiple testing using Bonferroni and Tamhane correction for homogeneity and heterogeneity of variance, respectively. The significant threshold of four comparisons of each test was set at p value < 0.05.

Results
Characteristics of study populations

Characteristics of Thai HIV-1 seronegative individuals (Healthy), HIV-1 seronegative IVDUs (IVX), HIV-1 seropositive individuals (HIV-1+ve) and HIV-1 seropositive IVDUs (IVH) in this study were shown in **Table 1**. Healthy group did not have any vaccination at least one year prior to this study. In IVX group, there was only one participant with history of Hepatitis B virus infection. All subjects in IVH group had

Figure 1. Representative flow cytometric two-parameter dot-plots on NK cytotoxicity test showing Forward Scatter (FSC) vs. Side Scatter (SSC) of NK (effector) cells and EGFP-K562 (target) cells A) and logarithmic EGFP vs. propidium iodide expression of live and dead effector vs. target cells (B). Cells at the lower right (LR) quadrant are lived target cells whereas the red and green fluorescent on the upper right (UR) quadrant are dead target cells. Cells at the upper left (UL) quadrant are defined as the autodamaged or potentially lysed effector cells or target cells with decreased EGFP whereas the lower left (LL) quadrant represents the living effecter cells or living target cells with weak green fluorescence.

Table 1. Demographics and characteristics of the study populations.

Group	Subjects	Age (yrs) Mean ± SD	Gender		Injecting drug (%)			Inhalation drug (%)	
			Male	Female	Heroin	Methamphetamine	Domicum	Methamphetamine	Cannabis
Healthy	30	30 ± 6.7	23	7	-	-	-	-	-
IVX	30	39 ± 6.9	22	8	66.6	52.4	28.6	68.8	56.3
HIV-1+ve	30[a]	31 ± 9.1	22	8	-	-	-	-	-
IVH	30[b]	39 ± 8.1	24	6	37.5	58.3	54.2	83.3	61.1

IVX = HIV-1 seronegative IVDUs; IVH = HIV-1 seropositive IVDUs
[a] unknown history of antiretroviral drug treatment; [b] all subjects received tenofovir as antiretroviral drugs.

received tenofovir as antiretroviral drugs. All IVDUs subjects had history for multiple intravenous and inhalation drug behaviors. Their drugs used within the 3-month period prior to blood collection were mainly heroin, methamphetamine, domicum and cannabis for both IVX and IVH groups. Within the IVX group, the percentage of participants that used injecting drugs was 66% heroin, 52.4% methamphetamine and 28.6% domicum, and inhalation drugs was 68.8% methamphetamine and 56.3% cannabis (**Table 1**). For the IVH group, the percentage was 37.5% heroin, 58.3% methamphetamine and 54.2% domicum, and inhalation drugs was 83.3% methamphetamine and 61.1% cannabis (**Table 1**).

Percentages and absolute counts of NK cells, helper CD4$^+$ T cells and cytotoxic CD8$^+$ T cells in the study populations

Mean percentages and absolute counts of each lymphocyte subset among the study populations were compared and shown in **Table 2**. The mean percentages of helper CD4$^+$ T cells of IVH group and HIV-1+ve group were significantly lower than those of IVX group and healthy group. No statistically significant difference among the two HIV-1 infected groups (IVH group vs. HIV-1+ve group) and among the two HIV-1 seronegative groups (IVX group vs. healthy group) were found. The mean absolute counts of helper CD4$^+$ T cells from IVH group were significant decreased (p ≤ 0.001) when compared with those from HIV-1+ve, IVX, and the healthy groups. Interestingly, the

absolute counts of helper CD4$^+$ T cells from IVX group were significantly higher than those of healthy and HIV-1+ve groups (p value ≤ 0.05) while those of healthy and HIV-1+ve groups were comparable.

For cytotoxic CD8$^+$ T cells, the mean percentages in HIV-1+ve group and IVH group were significantly higher (p ≤ 0.05) than those of healthy group and IVX group. No statistically significant differences among the HIV-1+ve and IVH groups and among the IVX and healthy groups were seen (**Table 2**). Comparison of the absolute counts of cytotoxic CD8$^+$ T cells among the study groups showed that HIV-1+ve group had a significant increase (p ≤ 0.05) in the absolute counts when compared with those of IVH, IVX and the healthy groups. Moreover, no significant difference among the healthy, IVX and IVH groups were observed.

Among the study groups, the mean percentage of NK cells was significantly decreased (p ≤ 0.05) in IVH group when compared to those from healthy group but did not show any significant difference to those of HIV-1+ve group and IVX group. No significant differences in mean percentages of NK cells were found among the HIV+ve, IVX and the healthy groups (**Table 2**). For the absolute counts of NK cells, the IVH group showed significant decrease (p ≤ 0.05) in the absolute counts when compared with those of HIV+ve, IVX and the healthy groups. No significant differences among the healthy, IVX and HIV-1+ve groups were found.

Table 2. Comparison of percentages and absolute counts of helper T cells (CD3$^+$CD4$^+$), cytotoxic T cells (CD3$^+$CD8$^+$) and NK cells (CD3$^-$CD16$^+$CD56$^+$) in the 4 study groups.

Parameter	Mean ± SD				p-value
	Healthy gr.	IVX gr.	HIV-1 +ve gr.	IVH gr.	
Helper T cells					
%	33.25 ± 5.58	36.39 ± 8.78	22.39 ± 9.71*	19.99 ± 6.36*	≤ 0.05
cells/μl	784 ± 261	1104 ± 526	732 ± 581	358 ± 206**	≤ 0.001
Cytotoxic T cells					
%	30.61 ± 6.07	26.07 ± 8.16	49.38 ± 13.21*	51.09 ± 9.52*	≤ 0.05
cells/μl	657 ± 268	757 ± 390	1380 ± 874*	948 ± 406	≤ 0.05
NK cells					
%	18.99 ± 5.30	15.62 ± 7.74	14.55 ± 10.87	11.10 ± 6.47$	≤ 0.05
cells/μl	458 ± 189	451 ± 303	380 ± 320	188 ± 115**	≤ 0.05

* Statistical difference when compared to the Healthy and IVX groups.
** Statistical difference when compared to the Healthy, IVX and HIV+ve groups.
$ Statistical difference when compared to the Healthy group.

Table 3. Comparison of NK cytotoxicity function in the 4 study groups.

E/T ratio	Mean ± SD of % lysis of NK cytotoxicity in				*p*-value
	Healthy gr.	IVX gr.	HIV-1 +ve gr.	IVH gr.	
80:1	41.78 ± 7.99	52.02 ± 13.68	41.06 ± 11.23	33.77 ± 10.02*	≤ 0.05
40:1	30.91 ± 8.77	35.58 ± 15.40	29.64 ± 8.29	23.20 ± 9.71*	≤ 0.05

* Statistical difference when compared to the Healthy, IVX, and HIV+ve groups.

NK cell cytotoxicity in the study populations

Comparison of the mean percentages of EGFP-K562 target cell lysis at the E:T ratios of 80:1 and 40:1 by NK cells from the 4 study groups showed that the IVH group showed significantly decreased of NK cytotoxicity (p ≤ 0.05) at the E:T ratio of 80:1 and 40:1 when compared to the other groups (**Table 3**). Interestingly, the mean lysis percentages of NK cytotoxicity in IVX group at both E/T ratios were significantly higher (p ≤ 0.05) than those in HIV-1+ve, IVH and the healthy groups, particularly at E:T ratio of 80:1. Moreover, no difference of the mean percentages lysis activity between the healthy and the HIV-1+ve groups were shown.

Discussion

It is estimated that worldwide there are almost 13 million people who are IVDUs. Out of these nearly 2 million, or 15%, are also living with HIV which is typically far greater than it is among the rest of the adult population, with IVDUs bearing a 28 times higher prevalence.[22] In Thailand, there were an estimated 440,000 people living with HIV in Thailand in 2015 with an estimation of adult HIV prevalence of 1.1% out of Thailand's population of more than 60 million. Among 6,900 new HIV infections in 2015, unsafe injecting drug use is the second biggest transmission route which account for 12%.[23] During HIV-1 infection several immunological abnormalities have been found in IVDUs.[5,8] It has been known that the increased risk for the disease progression in HIV-infected individuals is associated with the decline of helper CD4⁺ T cells and the accumulation of cytotoxic CD8⁺ T cells with a more rapid helper CD4⁺ T cell decline among HIV-1 infected IVDUs.[24] Biological factors such as effect of opioids, co-infection with other diseases such as TB or hepatitis C, even a difference in tropism with virulent strain of HIV transmitted among the IVDUs are all responsible for the faster decline in helper CD4⁺ T cells.[25,26] A decline in both percentages and absolute counts of helper CD4⁺ T cells with marked increases in percentages and absolute counts of cytotoxic CD8⁺ T cells in our IVH group support the above findings. Although there was no history of how fast the decrease of helper CD4⁺ T cells in our IVH group as only one blood sample at one time point was obtained, our IVH group showed more helper CD4⁺ T cell decline than those in HIV+ve group. This may indicate the problems with an irregular adherence to antiretroviral drugs, loss of follow-up or lower access to health services in our IVH group. Unlike the decline helper T cells found in IVH group, our HIV+ve group showed higher helper CD4⁺ T cell counts than the IVH group implying that there was a good suppressing HIV replication in these asymptomatic HIV-1 infected blood donors. Unfortunately, the history of antiretroviral drug treatment was not available for this group.

NK cells have been described for the innate mechanism as the first line defense against HIV-1 infection and may help mediating adaptive immune responses.[10-12] It has been shown that NK cell effect or function that mediated NK cell cytotoxicity are impaired during the course of HIV-1 disease[26] but enhanced during HIV-1 viremia.[27] Previous studies on the NK profiles from the cohort of HIV-1 exposed, uninfected IVDUs demonstrated the enhancement of NK activity, high NK activation as represented by CD38⁺ cells, and the CD4 and CD8 cell-mediated resistance to HIV-1 infection.[18,28,29] However, there is limited information available regarding the effect of HIV-1 infection on the NK profile in Thai IVDUs. Our NK cytotoxicity study in IVDUs showed significantly decreased of lysis activity in IVH group when compared to those of healthy, HIV-1+ve and IVX groups. When defining the percentage and absolute count of NK cells, our study showed significant decrease of both the percentage and the absolute count of NK cells in IVH group when compared to those of healthy, HIV-1+ve and IVX groups. This data suggested the inverse effect to the NK cell numbers due to HIV-1 infection along with the use of injecting drugs. Our findings also support that the drug abuse has immune-modulating effects which could alter the progression of HIV infection.[30,31]

Of interest is that the NK functional activity in our IVX group was significantly increased when compared to the other 3 groups. The increased NK cell lysis activity in the IVX who are a high-risk group, could due to different mechanisms related either to immune responses and/or to genetic background contribute to the resistance to infection in the highly exposed but uninfected (EU) IVDUs. Our results support the contentions of enhanced innate immune cell function in EU individuals especially when compare with IVDUs who became HIV-1 infected.[28] There was no difference of the mean percentages NK celllys is activity between the healthy and the HIV-1+ve groups. This may be due to the asymptomatic stage of our HIV+ve individuals whose NK cell functions were still normal. When defining the percentage and absolute count of NK cells, our study demonstrated that not only there was no significant difference of the mean percentages of NK lysis activity among the HIV+ve, IVX and the healthy groups, but also there was no difference in percentages and the absolute counts of NK cells. Our findings are in line with de Souza et al. who reported that NK cell cytotoxicity and NK cell counts are not different between Thai HIV-1 seronegative and Thai HIV-1 seropositive subjects.[32]

In conclusion, our study shows that IVHs have alterations in the lymphocyte subsets evidenced by a decrease in helper

CD4$^+$ T cells and an increase in cytotoxic CD8$^+$ T cells along with a lower number of NK cells and their impaired cytotoxic function. The data suggest that the failure of innate immune NK cell function and their number with possible link to decrease in helper CD4$^+$ T cells and increase in cytotoxic CD8$^+$ T cells, may contribute to the ineffective immune surveillance and potentially predisposing them to progressive disease.

Acknowledgements

References

1. UNAIDS. Joint United Nations Programme on HIV/AIDS:Global report on the global AIDS epidemic 2013[Internet].Geneva:UNAIDS; c2017 [cited 2017 Oct 25]. Available from:
   http://www.unaids.org/globalreport/global_report.html
2. AVERT. Global information and education on HIV and AIDS: HIV and AIDS in Thailand 2017 [Internet].UK: AVERT; c2017 [cited 2017 Oct 31]. Available from:
   https://www.avert.org/professionals/hiv-around-world/asia-pacific/thailand#footnote32_3q0sa9g
3. UNAIDS. Joint united nations programme on HIV/AIDS:Global report on the global AIDS epidemic 2010[Internet]. Geneva:UNAIDS; c2017 [cited 2017 Oct 25]. Available from:
   http://www.unaids.org/globalreport/global_report.html
4. Tovanabutra S, Beyrer C, Sakkhachornphop S, Razak MH, Ramos GL, Vongchak T, et al. The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002. AIDS Res Hum Retroviruses. 2004;20:465-75.
5. Wasi C, Herring B, Raktham S, Vanichseni S, Mastro TD, Young NL, et al. Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E. AIDS. 1995;9:843-9.
6. Xiridou M, van Griensven F, Tappero JW, Martin M, Gurwith M, Vanichseni S, et al. The spread of HIV-1 subtypes B and CRF01_AE among injecting drug users in Bangkok, Thailand. J Acquir Immune Defic Syndr. 2007;45:468-75.
7. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol. 2006;1:280-95.
8. Friedman H, Pross S, Klein TW. Addictive drugs and their relationship with infectious diseases. FEMS Immunol Med Microbiol. 2006;47:330-42.
9. Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, et al. The trafficking of natural killer cells. Immunol Rev. 2007;220:169-82.
10. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44-9.
11. Rousalova I, Krepela E. Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol. 2010;37:1361-78.
12. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002;2:735-47.
13. Ananworanich J, Apornpong T, Kosalaraksa P, Jaimulwong T, Hansudewechakul R, Pancharoen C, et al. Characteristics of lymphocyte subsets in HIV-infected, long-term nonprogressor, and healthy Asian children through 12 years of age. J Allergy ClinImmunol. 2010;126: 1294-301.
14. Zucchini N, Crozat K, Baranek T, Robbins SH, Altfeld M, Dalod M. Natural killer cells in immunodefense against infective agents. Expert Rev Anti Infect Ther. 2008;6:867-85.
15. Baldwin GC, Roth MD, Tashkin DP. Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J Neuroimmunol. 1998;83:133-8.
16. Poli G, Introna M, Zanaboni F, Peri G, Carbonari M, Aiuti F, et al. Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome. Clin Exp Immunol. 1985;62:128-35.
17. Ravet S, Scott-Algara D, Bonnet E, Tran HK, Tran T, Nguyen N, et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood. 2007; 109:4296-305.
18. Tomescu C, Duh FM, Lanier MA, Kapalko A, Mounzer KC, Martin MP, et al. Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users. AIDS. 2010;24:2151-60.
19. Kantakamalakul W, Jaroenpool J, Pattanapanyasat K. A novel enhanced green fluorescent protein (EGFP)-K562 flow cytometric method for measuring natural killer (NK) cell cytotoxic activity. J Immunol Methods. 2003;272:189-97.
20. Nicholson JKA, Jones BM, Hubbard M. CD4 T-lymphocyte determinations on whole blood specimens using a single-tube three-color assay. Cytometry. 1993;14:685-9.
21. Pattanapanyasat K, Pengruangrojanachai V, Thepthai C, Suwanagool, Wasi C. Flow cytometric three-color determination of CD4 T-lymphocytes on blood specimens from AIDS patients who have a large number of contaminated non-lymphocytes. Asian Pac J Allergy Immunol. 1994;12:105-9.
22. UNAIDS. People who inject drugs. The GAP report 2014[Internet]. Geneva: UNAIDS; c2017 [cited 2017 Oct 31]. Available from: http://www.unaids.org/sites/default/files/media_asset/05_peoplewhoinjectdrugs.pdf
23. Global AIDS update 2016 - unaids. Global AIDS Response Progress Reporting (GARPR) 2016[Internet]. Geneva: UNAIDS; c2017 [cited 2017 Oct 25]. Available from: http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf
24. Meijerink H, Wisaksana R, Iskandar S, den Heijer M, van der Ven AJAM, Alisjahbana B, et al. Injecting drug use is associated with a more rapid CD4 cell decline among treatment naïve HIV-positive patients in Indonesia. J Int AIDS Soc. 2014;17:18844.
25. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS. 1998;12:381-8.
26. Kottilil S, Chun TW, Moir S, Liu S, McLaughlin M, Hallahan CW, et al. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis. 2003;187:1038-45.
27. Borrow P, Bhardwaj N. Innate immune responses in primary HIV-1 infection. CurrOpin HIV AIDS. 2008;3:36-44.
28. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol. 2003;171: 5663-7.
29. Truong LX, Luong TT, Scott-Algara D, Versmisse P, David A, Perez-Bercoff D, et al. CD4 cell and CD8 cell-mediated resistance to HIV-1 infection in exposed uninfected intravascular drug users in Vietnam. AIDS. 2003;17:1425-34.
30. Donahoe RM, Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol. 1998;83:77-87.
31. Steele AD, Henderson EE, Rogers TJ. Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology. 2003;309:99-107.
32. de Souza MS, Karnasuta C, Brown AE, Markowitz LE, Nitayaphan S, Garner RP, et al. A comparative study of the impact of HIV infection on natural killer cell number and function in Thais and North Americans. AIDS Res Hum Retroviruses. 2000;16:1061-6.

Instructions for authors

Please submit your manuscript via on-line submission system at the following address: http://www.apjai-journal.org.

Mission Statement

The Asian Pacific Journal of Allergy and Immunology (APJAI) publishes original research articles, clinical observations, case reports and reviews on various aspects of allergy and immunology provided that they have not been, and will not be, published elsewhere in whole, or in part, without the Editor's permission. Papers accepted become the copyright of the Journal. Authors are responsible for all statements in articles submitted to the APJAI.

Journal Publication Policies and Procedures

The APJAI will consider for publication those papers directly related to allergy and immunology and has agreed to follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (the "Uniform Requirements") of the International Committee of Medical Journal Editors (ICMJE), the full text of which is available at http://www.icmje.org. The manuscript submission instructions for the APJAI submission are consistent with the 2009 version of the Uniform Requirements. The Editor assumes that upon submission of a manuscript, all listed authors have agreed with the APJAI policies. Manuscripts that do not meet these guidelines will be returned to the submitting author for revision prior to any further consideration for peer review.

Submissions will be considered for publication in APJAI only if they are submitted solely to APJAI. It must not have been previously published and must not be under consideration for publication elsewhere. All published manuscripts become the permanent property of the APJAI and may not be published elsewhere without written permission.

Ethical Approval of Studies and Informed Consent

For all research studies involving human subjects or research material derived from humans, a statement describing approval by the appropriate Institutional Review Board (IRB) is required in the Methods Section. Authors must declare how and if the informed consents were obtained from the study participants, if the study is conducted in humans, in the Methods Section. Studies exempted from IRB approval by their respective boards should be indicated in the Methods Section. Institutional Review Board approval and informed consent statements are not required for Case Reports. Studies involving experimental animals must include a statement in the Methods Section indicating that institutional or national guidelines were followed for the care and use of the animals. Failure to comply with this requirement will result in the manuscript being returned without review.

Clinical Trial Registration

APJAI requires investigators to preregister their clinical trials in a public trials registry approved by WHO (http://www.who.int/ictrp/network/primary/en/).

APJAI has adopted the WHO's definition of a clinical trial: "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes." The clinical trial registration number and name of the registry should be clearly identified on the title page and in the Methods Section.

Manuscript Preparation and Submission Requirements (NEW!!)

The authors must submit the cover letter, title page, abstract, manuscript text, tables, figures, and/or supplement files. Please read the instruction in the online submission system carefully as many changes have been implemented. All manuscripts are subjected to open peer-review.

Before submitting a manuscript, please gather the following information:

- All Author
    - First and Last Names
    - Postal Addresses
    - Work Telephone Numbers (for Corresponding Author only)
    - E-mail addresses
- Title (you can copy and paste this from your manuscript)
- Abstract (you can copy and paste this from your manuscript)
- Manuscript files in Word (Please make sure the "Language" is "English (U.S.)" via Tools->Language->Set Language), WordPerfect, EPS, text, Postscript, PDF, or RTF format.
- Cover Letter, including job title and institution for EVERY Author listed on the manuscript.
- Figures/Images should be in TIFF, GIF, JPG, PDF, Postscript, or EPS format.

Submission Process

The four steps of the submission process are: Files, Manuscript Information, Validate, and Submit. The four steps each contain sub-steps that can be accessed by clicking on their respective tabs. Navigating through this "Tab View" will save any entered information each time a new tab is clicked (or the boxes "Save and Continue" and "Next" are clicked). Each step and sub-step is listed below:

1. **Files**
    - **Upload Files**
        A screen asking for the actual file locations (via an open file dialog) will appear. After completing this screen, your files will be sent to be converted to PDF for the peer review process.
    - **Remove Files**
        Allows the user to remove previously uploaded files.
    - **Replace Files**
        Allows the user to replace any previously submitted files with another file.
    - **File Type**
        This tab prompts the user to choose the "file type" that corresponds to the upload document. Though the file types can vary from journal to journal, the five basic types of files are, Author Cover Letter, Article File, Figure, Table, Supplemental Material.

- **File Description**

  When uploading a file type labeled "Figure", "Table", or "Supplemental Material" it is required to give a brief description of the content that is included in the file.
- **File Order**

  This tab allows the user to rearrange files to be displayed at the author's discretion. This tab also gives the option to merge PDF files into a single PDF file to display to the Editor and Reviewers. Upon completion the user must check the checkbox indicating completion of the ordering and selection process.

2. **Manuscript Information**
   - **Title, Abstract**

     It is require for the user to provide a Title for manuscript as well as a Running Title and an Abstract. The Title, Running Title, and Abstract all have word or character limits. (See details in Manuscript Format)
   - **Authors**

     This tab prompts the user to submit General Information about the author. The fields marked with an asterisk (*) are required, and need to be completed to continue the submission process.
   - **Keywords & Subject Areas**

     A screen where the author provides at subject areas of the manuscript from the list provided. If needed, the author can provide keywords for the manuscript by typing it in any boxes that might be provided.
   - **Detailed Information**

     This screen asks for more detailed information regarding the manuscript. Though the questions in this tab may vary from journal to journal, typical questions include "Conflict of Interest" and "Dual Publication".
   - **Author Review Suggestions**

     This screen allows the user to provide "suggested reviewers" to include for the revision process. The author can also provide reviewers to exclude from the revision process.

3. **Validate**
   - **Approve Files**

     The screen allows the user to verify that the manuscript has been uploaded and converted to the PDF format correctly.
   - **Approve Manuscript**

     This screen provides the user with all the information gathered from the submission process. It will provide a summary of all of the data entered so far, with the option to change any of those items.

4. **Submit**

   This screen is the final step of the submission process. The system will check to make sure everything is completed before the manuscript is submitted. If the manuscript is ready for submission, then there will be text that reads: "Your manuscript is ready to be submitted. Click the link below to finalize your submission." Otherwise, it will ask that you modify your submission to fulfill all of the submission requirements.

5. **Submission Fee**

   A nonrefundable processing fee of USD $40 is due upon submission. No submission fee is required for invited review article. If a fee is required, you will be asked to pay it online using credit card at the time of submission. Please note that purchase orders and bank wire transfers cannot be accepted for the processing fee. Manuscript will not be processed further unless the submission fee is received by APJAI editorial office.

6. **Manuscript Format**

   Manuscripts should be type-written in English with font style Times New Roman, font size 12. All pages should be numbered consecutively at the top right-hand corner, beginning with the title page. The manuscript must display continuous line numbers (1, 2, 3, and so forth) in the left margin, beginning with the title page. (Line numbering can be added from the Page Setup or Format menu of word processing programs.) All sections of the manuscript should be typed, double-spaced with margins of at least one inch on all sides and arranged in the following order:

   6.1 The title page MUST have the following information
   - Title of the manuscript
   - first and last names of the authors; no initials allowed unless it is a middle name
   - authors and their perspective highest academic degree(s)
     example: Jane S Doe, MD, PhD [1], John K Watson, MSc [2], Katherine Gibson, BSc [3,4]
   - Authors' affiliation(s)
   - Short running title
   - Name of the corresponding author
   - Address of the corresponding author including telephone, fax number and email address
   - Clinical trial registration number (if applicable)
   - word count for abstract
   - word count for text
   - Indicate total number of references
   - Indicate total number of tables and figures (no more than a total of 2 figures and tables combined).
     Example: 250 abstract; 3500 text; 35 references; 2 tables; 4 figures

   6.2 Structured abstract with the following subheadings and not more than 250 words total (including the subheadings)

   Abstract must be written in a structured format with the following headings: background; objective; methods; results; and conclusion. The major points of the article should be summarized in 150 (case reports) to 250 words (original research and review articles), in the order of their appearance in the manuscript. Abbreviations should be kept to an absolute minimum. References are not allowed in the abstract.

   Keywords (at least 5 words or key phrases)

   A minimum of 5 key words or brief phrases should be listed below the abstract for indexing purposes. The Medical Subject Headings (MeSH) used by the US National Library of Medicine's Index Medicus (MEDLINE) are preferred.

6.3 Main text

This section must have the following headings: Introduction, Methods, Results, Discussion, and Conclusion. In the text, cite references sequentially in superscript arabic numerals, e.g., [1,2,3] .Tables must be numbered sequentially in the text with Arabic numerals (1, 2, 3, 4, etc). Figures must be numbered sequentially in the text with Arabic numerals (1, 2, 3, 4, etc).

Introduction

This section should state the specific purpose, research objective, or hypothesis of the study and should provide a context or background information for the study. The aims of the manuscript should be clearly stated. Papers most closely related to the issue of the study may be mentioned. The introduction should not contain either findings or conclusions.

Methods

This section should be concise but provide sufficient detail to allow the work to be repeated by others. The source of material should be given in detail, where possible. Describe the design, subjects, setting, interventions, and main outcome measures. The explanation of the experimental methods provides technical information, apparatus details, and procedures. Describe statistical methods with sufficient detail to enable a reader with access to the original data to verify the reported results. For all research studies including human subjects (excluding Case Reports) the specific IRB that has approved the research must be indicated. Additionally a statement that informed consent was obtained from all research participants must be included. The clinical trial registration number and place of registry should be informed for clinical trial studies.

Results

Describe the experimental data and results as well as the particular statistical significance of the data. Results should be presented in a logical sequence in the text, tables and figures. Excessive repetition of the same data in different forms should be avoided. The Consolidated Standards of Reporting Trials (CONSORT) statement is a set of guidelines for reporting on the methods and results of randomized and nonrandomized medical research studies and is available at the following Website: http://www.consort-statement.org.

Discussion

Provide and quantify the main outcomes of the study. The data should be interpreted concisely, without repeating data already presented in the results section. Identify limitations of the presented data including plausible explanations for discrepancies between the data and the literature, any differences not expected from the initial hypothesis presented in the introduction and a measured description of the conclusions of the study with implications for future research, biological understanding and/or clinical applications.

6.4 Acknowledgements

Conflict of interest (in the past 3 years)
Source of funding with grant numbers (if applicable)
Author contributions

6.5 References

not more than total of 35 for original research papers
not more than 70 for review papers
Vancouver style (you can download the APJAI endnotes style here (URL)

Examples
1   Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935:40-6.
2   Corporate Author Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002;40:679-86.

Books and other monographs
1   Personal Author(s) Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.
2   Chapter in a Book Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. p. 93-113.

6.6 Figure legends

Figure legends should be typewritten, double-spaced, and listed on a separate page after the tables. They should not appear on the figures. List all of the figure titles in the figure legend. The legends should identify the data or subject being presented and its legend are understandable without reference to the text. Figures should be professionally drawn and photographed. Colored photographs may be published and additional expense will be paid by the authors. Titles and detailed explanations belong in the figure legends, not on the figures themselves. Photomicrographs must have internal scale markers. Symbols, arrows, or letters used in the photomicrographs should contrast with the background. If a figure has been published, acknowledge the original source and submit written permission from the copyright holder to reproduce the material.

6.7 Tables

Tables should be numbered in the order in which they are first cited in the text with Arabic numerals (1, 2, 3, 4, etc). They should be on separate pages, one table per page. Each table should have a concise heading that makes it comprehensible without reference to the text of the article. Use horizontal lines only at the top and bottom of the table and between column headings and the body of the table. Use no vertical lines. Explain any nonstandard abbreviations in the footnote of the table, e.g., Abbreviations: CT, computed tomography; MRI,

magnetic resonance imaging; OR, odds ratio. Footnotes in captions should appear at the bottom of the table

Please use the program's page break function to begin each section on a new page.

6.8 Figure

Figures (graphs, charts, photographs, and illustrations) should be numbered in the order in which they are first cited in the text.

All figures must be numbered sequentially with Arabic numerals (1, 2, 3, 4, etc). . Graphics should be saved in CMYK (cyan, magenta, yellow, black) rather than RGB (red, green, blue). The resolution specification for TIFF and EPS files is 800 dpi for monochrome, figures that are black and white only and line shots; 250-300 dpi for gray/ CMYK or color photographs, and 600 dpi for combinations, such as photographs labeled with letters or other markings. One figure per page

Manuscripts should be written in proper and clear English so that they are understandable to any reader who is not a specialist in the field. Authors may be requested to have the English of the manuscript checked and improved by language editing services before submission. All measurements must be given in SI units as outlined in the latest edition of Units, Symbols and Abbreviations: A Guide for Medical and Scientific Editors and Authors (Royal Society of Medicine Press, London). However, liter and molar are permitted. Abbreviations should be used sparingly and only where they reduce repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation. All manuscripts must be submitted via online at the following address: http://www.apjai-journal .org/.

Article Types

The APJAI publishes original articles, review articles, and case reports. Topics of interest include all subjects that relate to the basic and clinical aspects of allergy and immunology.

- **Original Research Articles:** The text of original articles should be divided into sections with the following headings in this order: Introduction, Methods, Results, Discussion, and Conclusion. The total text should not exceed 3,500 words (excluding the Abstract, References, and Figure/Table Legends). These should describe fully, but as concisely as possible, the results of original clinical and/or laboratory research. Original articles should have a structured abstract with the following headings: Background, Objective, Methods, Results and Conclusions (maximum 250 words). A minimum of 5 keywords for indexing, and no more than 35 references are required. Text should not exceed 3,500 words. Advice on appropriate sectioning of original articles can be found in the ICMJE's Uniform Requirements. Each original article may be accompanied by a combination of no more than 6 figures and tables. Original article manuscripts that are determined to significantly exceed these limits may be returned

to the authors for shortening prior to review. The manuscript should be organized in the following order: title page WITH the names of the authors and affiliations (please see title page requirement mentioned above); abstract and key words; main text; acknowledgements; references; figure legends; tables (each table complete with title and footnotes), and figures. Figures should look sharp and crisp when viewed at 100% magnification. Please note that should your manuscript be accepted, the journal may request for higher resolution TIFF or EPS files.

- **Review Articles:** Review articles are mostly invited by the Editors. Authors interested in submitting a review article should contact the Editor-in-Chief in advance to determine the appropriateness of any proposed review prior to submitting a full manuscript. Review articles address a specific question or issue that provide an evidence-based, review on a focused topic, either clinical or basic science. Review articles should have a structured abstract (250 words or less) with the following headings Objective, Data Sources, Study Selections, Results and Conclusion, a minimum of 5 keywords, and no more than 70 references. Text should not exceed 5,000 words and should be organized into the following sections: Introduction, Body, Discussion and Conclusions.

- **Case Reports:** Case Reports should have an unstructured abstract of no more than 150 words, a minimum of 5 keywords, a maximum of 2 tables or figures and 20 references. The main text should not exceed 1,500 words and should be organized into the following sections: Introduction, Report of Case and Discussion. A fully structured abstract is not necessary for a Case Report. For guidance on acceptable handling of photographs and other safeguards of patient confidentiality and anonymity, refer to section II.E.1 of the ICMJE's Uniform Requirements: Patients and Study Participants.

- **Short Communications:** Short communications are short research articles intended to present exciting finding. Short communications are limited to 1000 words for the body of the text, 8 references and may include no more than 1 figure or 1 table. Manuscripts should be organized as described for original research article and abstract.

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party. Authors must omit from their manuscripts any identifying details regarding patients and study participants, including patient names, initials, social security numbers, and hospital numbers. Patient details may be included only if they are essential for scientific purposes and the authors have obtained written informed consent from the patient, parent, or guardian for publication purposes.

Publication Fees

A sum of US $400.00 is charged to the corresponding author of each article published in the APJAI. A pdf file will be provided to the corresponding author. In case of English editing required by reviewers, US $80.00 is charged additionally. If the manuscript has been checked by a certified institute, please submit the certificate. Additional fee for reprints and color illustrations are charged to the authors separately.